US20080160526A1 - Mismatched end dna ligase - Google Patents
Mismatched end dna ligase Download PDFInfo
- Publication number
- US20080160526A1 US20080160526A1 US11/871,023 US87102307A US2008160526A1 US 20080160526 A1 US20080160526 A1 US 20080160526A1 US 87102307 A US87102307 A US 87102307A US 2008160526 A1 US2008160526 A1 US 2008160526A1
- Authority
- US
- United States
- Prior art keywords
- dna
- cernunnos
- ligation
- ligase
- joining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004414 DNA Proteins 0.000 title claims abstract description 133
- 102000003960 Ligases Human genes 0.000 title abstract description 39
- 108090000364 Ligases Proteins 0.000 title abstract description 39
- 102100028156 Non-homologous end-joining factor 1 Human genes 0.000 claims abstract description 121
- 101000578059 Homo sapiens Non-homologous end-joining factor 1 Proteins 0.000 claims abstract description 118
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 68
- 229920001184 polypeptide Polymers 0.000 claims abstract description 65
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 65
- 102000012410 DNA Ligases Human genes 0.000 claims abstract description 41
- 108010061982 DNA Ligases Proteins 0.000 claims abstract description 41
- 102100027828 DNA repair protein XRCC4 Human genes 0.000 claims abstract description 31
- 101000649315 Homo sapiens DNA repair protein XRCC4 Proteins 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims description 48
- 230000000694 effects Effects 0.000 claims description 45
- 238000006243 chemical reaction Methods 0.000 claims description 31
- 229910019142 PO4 Inorganic materials 0.000 claims description 27
- 239000000758 substrate Substances 0.000 claims description 24
- 102000040430 polynucleotide Human genes 0.000 claims description 15
- 108091033319 polynucleotide Proteins 0.000 claims description 15
- 239000002157 polynucleotide Substances 0.000 claims description 15
- 239000010452 phosphate Substances 0.000 claims description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 10
- 239000011541 reaction mixture Substances 0.000 claims description 9
- 102000053602 DNA Human genes 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 43
- 102000004169 proteins and genes Human genes 0.000 abstract description 42
- 238000005304 joining Methods 0.000 description 69
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 57
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 54
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 description 53
- 101710157074 DNA-dependent protein kinase catalytic subunit Proteins 0.000 description 52
- 125000003729 nucleotide group Chemical group 0.000 description 41
- 235000018102 proteins Nutrition 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 37
- 239000002773 nucleotide Substances 0.000 description 33
- 239000011780 sodium chloride Substances 0.000 description 27
- 239000000872 buffer Substances 0.000 description 24
- 230000006780 non-homologous end joining Effects 0.000 description 20
- 239000012634 fragment Substances 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 18
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 238000007792 addition Methods 0.000 description 16
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 14
- 108010060248 DNA Ligase ATP Proteins 0.000 description 12
- 102000008158 DNA Ligase ATP Human genes 0.000 description 12
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 12
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 12
- 239000000499 gel Substances 0.000 description 11
- 235000021317 phosphate Nutrition 0.000 description 11
- 230000014759 maintenance of location Effects 0.000 description 10
- 239000000284 extract Substances 0.000 description 9
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 9
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 8
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 230000005782 double-strand break Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 6
- 102100036973 X-ray repair cross-complementing protein 5 Human genes 0.000 description 6
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000002523 gelfiltration Methods 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 241000701447 unidentified baculovirus Species 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 101000804921 Homo sapiens X-ray repair cross-complementing protein 5 Proteins 0.000 description 5
- 101710127639 Non-homologous end-joining factor 1 Proteins 0.000 description 5
- 101710163270 Nuclease Proteins 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 4
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 4
- 239000013599 cloning vector Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- -1 aromatic amino acids Chemical class 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 108700020463 BRCA1 Proteins 0.000 description 2
- 101150072950 BRCA1 gene Proteins 0.000 description 2
- 102000001421 BRCT domains Human genes 0.000 description 2
- 108050009608 BRCT domains Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100025401 Breast cancer type 1 susceptibility protein Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000701533 Escherichia virus T4 Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 102000055340 human NHEJ1 Human genes 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 230000005257 nucleotidylation Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000012536 storage buffer Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010063905 Ampligase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101700002522 BARD1 Proteins 0.000 description 1
- 102100028048 BRCA1-associated RING domain protein 1 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 102100027834 DNA repair protein XRCC1 Human genes 0.000 description 1
- 101710147739 DNA repair protein XRCC1 Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 101900063352 Escherichia coli DNA ligase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000581326 Homo sapiens Mediator of DNA damage checkpoint protein 1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010025026 Ku Autoantigen Proteins 0.000 description 1
- 102000015335 Ku Autoantigen Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100027643 Mediator of DNA damage checkpoint protein 1 Human genes 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241001661355 Synapsis Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 101710124921 X-ray repair cross-complementing protein 5 Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000012361 double-strand break repair Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000034435 immune system development Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/50—Other enzymatic activities
- C12Q2521/501—Ligase
Definitions
- DNA ligases act to create a phosphodiester bond between strands of DNA or RNA.
- DNA ligase connects broken DNA strands to form covalent phosphodiester bonds between 3′ hydroxyl ends of one nucleotide with the 5′ phosphate end of another, using ATP in the process.
- the known DNA ligases in mammalian cells include DNA ligase I, which ligates Okazaki fragments during lagging strand DNA replication.
- DNA ligase III complexes with DNA repair protein XRCC1 to aid in sealing base excision mutations and recombinant fragments
- DNA ligase II is an alternatively spliced form of DNA ligase Ill.
- DNA ligase IV complexes with XRCC4 and catalyzes the final step in the non-homologous end joining DNA double-strand break repair pathway. It is also required for V(D)J recombination, the process which generates diversity in immunoglobulin and T-cell receptor loci during immune system development.
- DNA ligases have become an indispensable tool in modern molecular biology research for generating recombinant DNA sequences.
- DNA ligases are used with restriction enzymes to insert DNA fragments, often genes, into plasmids.
- Common commercially available DNA ligases were originally discovered in bacteriophage T4, E. coli or other bacteria. Using these enzymes, the most efficient way for a ligase to link DNA fragments is to connect two sticky ends together from a restriction digest. The hydrogen bonds between the complementary bases aid ligase in holding the two ends together while the phosphodiester bond is formed.
- DNA double-strand breaks occur at random upon genotoxic stresses and represent obligatory intermediates during physiological DNA rearrangement events such as the V(D)J recombination in the immune system.
- DSBs which are among the most toxic DNA lesions, are repaired by either homologous recombination or nonhomologous end joining (NHEJ), preferentially by the nonhomologous end-joining (NHEJ) pathway in higher eukaryotes. Failure to properly repair DSBs results in genetic instability, developmental delay, and various forms of immunodeficiency.
- DNA-PK DNA-dependent protein kinase
- T4 DNA ligase unlike Escherichia coli DNA ligase, Taq DNA ligase and Ampligase, is able to join the ends of single-stranded DNA in the absence of any duplex DNA structure at the ligation site.
- T4 DNA ligase unlike Escherichia coli DNA ligase, Taq DNA ligase and Ampligase, is able to join the ends of single-stranded DNA in the absence of any duplex DNA structure at the ligation site.
- nontemplated ligation of DNA oligomers catalyzed by T4 DNA ligase occurs with a very low yield, and thus is insignificant in many molecular biological applications of T4 DNA ligase.
- DNA ligase enzymes are of commercial interest for catalysis of a variety reactions.
- the present invention provides a useful complex that acts as a single-strand DNA ligase.
- the present invention relates to a mismatched end DNA ligase.
- Conventional ligases join both strands of two DNA ends. The ends must be compatible, consisting of either two blunt ends, or two ends with overhanging single strands that are complementary to each other.
- the mismatched end DNA ligase of the invention will act on noncompatible DNA ends, ligating two single strands to each other even if the other two single strands are not compatible, thus the term “Mis-matched End (MEnd) DNA ligase”.
- a purified polypeptide composition where multiple polypeptides coordinate to catalyze ligation of mismatched DNA strands at high efficiency.
- a group of polypeptides may be referred to as a complex or association, although the term does not, in this context, imply direct molecular interaction between the different polypeptides.
- the polypeptides are eukaryotic proteins, e.g. proteins from animals, including mammals.
- the polypeptides of the association are Ku, Cernunnos, and XRCC4/Ligase4 (XL).
- This association can ligate DNA ends with a 3′ overhang to a recessed 5′ end, to a blunt end, or to a compatible end.
- the ligation efficiency of noncompatible ends is from around 10% of that seen for compatible ends.
- the proteins are Ku, Cernunnos, XRCC4/Ligase4 (XL) and DNA-PK.
- the invention in another embodiment, relates to an in vitro method of ligating nucleotides or nucleotide analogs or nucleic acids containing nucleotides or nucleotide analogs, comprising contacting polynucleotides or nucleic acids with polypeptides of the invention, wherein the ligase catalyzes a reaction of ligation of the nucleotides, nucleotide analogs or nucleic acids.
- the polynucleotides used in the methods of the invention may be RNA or DNA, including single-stranded RNA or DNA.
- the nucleotide analogs may contain modified bases, modified sugars and/or modified phosphate groups.
- a method is provided to screen candidate agents, e.g. polypeptides and associations thereof, for mis-matched end DNA ligase activity.
- a candidate agent is contacted with polynucleotides in a joining reaction.
- the polynucleotide substrate preferably has non-compatible ends.
- the efficiency of ligation may be assessed by various criteria, e.g. by PCR, using primers that amplify on ligated ends.
- the ability of a candidate agent to catalyze mis-matched end DNA ligation is evidenced by the ability to join mis-matched ends.
- FIGS. 1A-B Cernunnos stimulates joining of mismatched DNA ends.
- A Purification of NHEJ proteins. Commassie staining after SDS-PAGE shows our purified preparations of Ku, DNA-PKcs (Pk), Cernunnos (C), and XRCC4/Ligase IV (XL).
- B Cernunnos stimulates joining of non-cohesive ends by Ku, DNA-PKcs and XL. Linear DNA substrates were incubated with no protein (dark gray bars), Ku, DNA-PKcs and XL (light gray bars), or Ku, DNA-PKcs, XL and Cernunnos (black bars). The orientation of DNA is depicted in the upper left corner.
- FIGS. 2A-B Ku, DNA-PKcs, XL and Cernunnos act in concert to join mismatched 3′ overhangs.
- DNA substrates with mismatched 3′-3′ overhangs KpnI-SacI
- KpnI-SacI DNA substrates with mismatched 3′-3′ overhangs
- Concentrations of Ku, DNA-PKcs and XL were 5 nM, 5 nM and 0.5 nM, respectively.
- Cernunnos (C) was added at concentrations of: 0.05 nM, 0.1 nM, 0.5 nM, 2.5 nM, 5 nM and 15 nM. The point in the lower left shows the background PCR signal in the absence of protein. Error bars represent the variation in duplicate measurements.
- FIG. 3 Cernunnos promotes retention of overhanging ends.
- the DNA substrates had mismatched 3′-3′ ends (KpnI-SacI); blunt-3′ ends with 4 nucleotide overhangs (EcoRV-KpnI); or blunt-3′ ends with 2 nucleotide overhangs (EcoRV-SacII).
- KpnI-SacI mismatched 3′-3′ ends
- EcoRV-KpnI blunt-3′ ends with 4 nucleotide overhangs
- EcoRV-SacII blunt-3′ ends with 2 nucleotide overhangs
- FIG. 4 Ku, XL and Cernunnos join mismatched ends using the 5′ phosphate from only one end.
- DNA phosphatase Antarctic phosphatase, NEB.
- EcoRV* and KpnI* denote dephosphorylated DNA molecules.
- FIGS. 5A-D Ku, XL and Cernunnos join mismatched ends by ligation of one strand.
- A Schematic of the gel-based assay for joining. We incubated Ku, XL and Cernunnos (Ku/XL/C) or T4 ligase (T4) with a linear DNA substrate containing EcoRI-EcoRI, EcoRV-EcoRV or EcoRV-KpnI ends, digested the DNA products with XmnI, and used T4 polynucleotide kinase to radiolabel the DNA. Concentrations of XL and Cernunnos were 1 nM and 5 nM, respectively.
- ApoI digestion converted the 472 nt band to 415 nt and 57 nt bands, and the 281 nt band to 224 nt and 57 nt bands (lane 5).
- the intensities of the 472 nt and 415 nt bands were equivalent (lanes 3 and 5).
- MspA1I digestion converted the 472 nt band to a 36 nt band, and converted the 191 nt band to a 36 nt band (lane 7), demonstrating ligation of only one strand.
- FIG. 6 Addition of Cernunnos to Ku and XL promotes the retention of 3′ overhangs.
- the DNA substrates had mismatched blunt-3′ ends with four nucleotide overhangs (EcoRV-KpnI) or blunt-3′ ends with two nucleotide overhangs (EcoRVSacII).
- the junctions recovered from PCR amplification are depicted to show nucleotide addition (black background) and nucleotide deletion (white background).
- FIG. 7 Addition of Cernunnos weakly promotes retention of 5′ overhangs.
- DNA substrates for joining were mismatched blunt-5′ ends EcoRV-BamHI (Upper) or EcoRV-EcoRI (Lower).
- EcoRV-BamHI Upper
- EcoRV-EcoRI Lower
- FIG. 8 Ku, DNA-PKcs, XL, and Cernunnos preparations lack detectable exonuclease activity.
- Polypeptides are provided that provides for efficient ligation of noncompatible DNA ends.
- An association of polypeptides is shown herein to provide for ligase activity that will act on noncompatible DNA ends.
- purified polypeptides are provided, where the association of the polypeptides in a reaction mixture catalyzes ligation of DNA single strands at high efficiency.
- the polypeptides may include Ku, Cernunnos, and XRCC4/Ligase4 (XL) and optionally DNA-PK.
- the invention in another embodiment, relates to a method of ligating nucleotides or nucleotide analogs or nucleic acids containing nucleotides or nucleotide analogs, comprising contacting polynucleotides or nucleic acids with the polypeptides of the invention, wherein the ligase catalyzes a ligation reaction of the nucleotides, nucleotide analogs or nucleic acids.
- the polynucleotides used in the methods of the invention may be RNA or DNA, including single-stranded RNA or DNA.
- the nucleotide analogs may contain modified bases, modified sugars and/or modified phosphate groups.
- Reactions of interest are performed in vitro, and join polynucleotides that have noncompatible ends, i.e. the terminus of one polynucleotide does not base pair with the terminus of the polynucleotide to be joined.
- Reactions of interest include reactions where a blunt terminus is joined to a blunt terminus; where a blunt terminus is joined to a 5′ overhang, where a blunt terminus is joined to a 3′ overhang, where two 5′ overhangs are joined, where two 3′ overhangs are joined, or where single stranded molecules are joined.
- at least one terminus will comprise a 5′ phosphate group. Where 3′ overhangs are ligated, the sequence of one of the overhangs is maintained.
- 5′ overhang or 3′ overhang
- the terminus comprises a single stranded region of at least one nucleotide, which may comprise 2, 3, 4, 5, or more nucleotides in a single stranded conformation, where the terminal nucleotide may be in a 3′ orientation or a 5′ orientation.
- a blunt terminus comprises no single stranded regions.
- Single-strand DNA ligase activity permits construction of recombinant DNA molecules without the usual limitation of compatible ends imposed by conventional ligases.
- Methods of use for the MEnd DNA ligase include, without limitation:
- PCR-amplified DNA Cloning of PCR-amplified DNA.
- Taq polymerase often catalyzes the non-templated addition of one or two bases, creating a 3′ overhang.
- PCR products are not blunt-ended and cloning efficiency is compromised by the need to use specialized cloning vectors.
- the MEnd single-strand DNA ligase will permit these fragments to be ligated directly into a blunt-ended cloning vector.
- Random cloning of genomic DNA Random cloning of genomic DNA. Current technologies for fragmenting genomic DNA leave ends with protruding single strands. If DNA polymerase is used to convert protruding 5′ overhangs into blunt ends, the genomic DNA fragments will have blunt ends and protruding 3′ overhangs. The MEnd single-strand DNA ligase will ligate these fragments directly onto a cloning vector.
- the MEnd DNA ligase of the invention is comprised of an association of polypeptides.
- the association is not required to be pre-assembled, it is sufficient to add the individual polypeptides in a reaction mixture, e.g. in the presence of polynucleotides to be ligated.
- one or more, or all of the polypeptides are purified prior to addition into a reaction mixture.
- a kit for ligation, where the kit comprises at least the polypeptides Ku, Cernunnos, and XRCC4/Ligase4 (XL) and optionally comprises DNA-PK.
- the polypeptides may be derived from any source, e.g. bacterial eukaryotic, etc.
- the polypeptides are derived from an animal source, e.g. from a mammalian source.
- the kit may further comprise a positive control mixture of nucleotides for ligation.
- the kit may further comprise buffer suitable for the reaction, for example provided as a concentrate, i.e. 10 ⁇ , 100 ⁇ , and the like.
- the enzymes of the invention may be “isolated”; as used herein, an “isolated” polypeptide has been completely or partially purified from other polypeptides.
- an isolated polypeptide of the invention may be substantially isolated with respect to the complex cellular milieu in which it naturally occurs.
- the isolated material will form part of a composition (for example, a crude extract containing other substances), buffer system or reagent mix.
- the polypeptide may be purified to essential homogeneity, for example as determined by PAGE or column chromatography such as HPLC.
- an isolated polypeptide can include a polypeptide that is synthesized chemically or by recombinant means.
- the present invention also pertains to polypeptide sequences that are not necessarily found in nature but that have substantially similar activity to the polypeptides described below.
- the invention also encompasses variations of the polypeptide sequences of the molecules providing for DNA ligase activity, such as those encoding active fragments or active derivatives of the polypeptides. Such variations can be naturally-occurring, or non-naturally-occurring, such as those induced by various mutagens and mutagenic processes.
- the mutation(s) can preferably preserve the three dimensional configuration of the binding site of the native polypeptide, or can preferably preserve the activity of the polypeptide (e.g., if the polypeptide is a DNA ligase, any mutations preferably preserve the ability of the enzyme to catalyze ligation of two polynucleotide strands).
- the presence or absence of activity or activities of the polypeptide can be determined by various standard functional assays including, but not limited to, assays for binding activity or enzymatic activity.
- the methods of the invention may utilize polypeptide sequences that have a substantial identity with the polypeptide sequences of known Ku, Cernunnos, XRCC4/Ligase4 (XL) and DNA-PK sequences, for example having at least about 10%, preferably at least about 20%, more preferably at least about 30%, more preferably at least about 40%, even more preferably at least about 50%, yet more preferably at least about 70%, still more preferably at least about 80%, and even more preferably at least about 90% identity, and still more preferably 95% identity, and providing for a molecule having at least about 10%, preferably at least about 20%, more preferably at least about 30%, more preferably at least about 40%, even more preferably at least about 50%, yet more preferably at least about 70%, still more preferably at least about 80%, and even more preferably at least about 90% of the activity of the molecules exemplified herein.
- XL XRCC4/Ligase4
- Variant and derivative sequences may include substantial regions of sequence identity, e.g. of at least about 50 contiguous amino acids identity, at least about 100 contiguous amino acids identity, at least about 150 contiguous amino acids identity, at least about 200 contiguous amino acids identity. Fragments may comprise at least about 50 contiguous amino acids, at least about 100 contiguous amino acids, at least about 150 contiguous amino acids, at least about 200 contiguous amino acids or more.
- An “active fragment,” as referred to herein, is a portion of polypeptide (or a portion of an active derivative) that retains the polypeptide's activity, as described above.
- Appropriate amino acid alterations can be made on the basis of several criteria, including hydrophobicity, basic or acidic character, charge, polarity, size, the presence or absence of a functional group (e.g., —SH or a glycosylation site), and aromatic character. Assignment of various amino adds to similar groups based on the properties above will be readily apparent to the skilled artisan; further appropriate amino acid changes can also be found in Bowie et al. (1990), Science, 247:1306-1310 (1990). For example, conservative amino acid replacements can be those that take place within a family of amino acids that are related in their side chains.
- polypeptides of the invention can also be fusion polypeptides comprising all or a portion (e.g., an active fragment) of the native polypeptide amino acid sequence fused to an additional component, with optional linker sequences.
- Additional components such as radioisotopes and antigenic tags, can be selected to assist in the isolation or purification of the polypeptide or to extend the half life of the polypeptide; for example, a hexahistidine tag would permit ready purification by nickel chromatography.
- the fusion protein can contain, e.g., a glutathione-S-transferase (GST), thioredoxin (TRX) or maltose binding protein (MBP) component to facilitate purification; kits for expression and purification of such fusion proteins are commercially available.
- GST glutathione-S-transferase
- TRX thioredoxin
- MBP maltose binding protein
- kits for expression and purification of such fusion proteins are commercially available.
- the polypeptides of the invention can also be tagged with an epitope and subsequently purified using antibody specific to the epitope using art recognized methods.
- Polypeptides described herein can be isolated from naturally-occurring sources (e.g., isolated from host cells). Alternatively, the polypeptides can be chemically synthesized or recombinantly produced.
- PCR primers can be designed to amplify the ORFs from the start codon to stop codon.
- the primers can contain suitable restriction sites for an efficient cloning into a suitable expression vector.
- the PCR product can be digested with the appropriate restriction enzyme and ligated between the corresponding restriction sites in the vector (the same restriction sites, or restriction sites producing the same cohesive ends or blunt end restriction sites).
- polypeptides of the present invention can be isolated or purified (e.g., to homogeneity) from cell culture (e.g., from culture of host cells infected with expression vector(s)) by a variety of processes. These include, but are not limited to, anion or cation exchange chromatography, ethanol precipitation, affinity chromatography and high performance liquid chromatography (HPLC). The particular method used will depend upon the properties of the polypeptide; appropriate methods will be readily apparent to those skilled in the art. For example, with respect to protein or polypeptide identification, bands identified by gel analysis can be isolated and purified by HPLC, and the resulting purified protein can be sequenced.
- the protein can be isolated by conventional means of protein biochemistry and purification to obtain a substantially pure product, i.e., 80, 95 or 99% free of cell component contaminants, as described in Jacoby, Methods in Enzymology, Volume 104, Academic Press, New York (1984); Scopes, Protein Purification, Principles and Practice, 2nd Edition, Springer-Verlag, New York (1987); and Deutscher (ed.), Guide to Protein Purification, Methods in Enzymology, Vol. 182 (1990).
- MEnd DNA ligase polypeptides as described herein can be used in a similar manner as other DNA ligases.
- the polynucleotides to be ligated are combined in a reaction mixture in vitro in the presence of an appropriate buffer, as exemplified in the Examples, ATP, and the polypeptides of the invention. As described herein, it is not necessary for the enzymes to have compatible ends.
- the reaction mixture is incubated for a period of time sufficient to allow for the desired level of ligation, e.g. for about 10, 30, 60 minutes or more.
- the polynucleotide substrate may be present at a concentration of from around 0.01 ⁇ M to around 100 mM, depending on the specific reaction, where smaller fragments may be present at a high molarity than larger fragments.
- the reaction is typically incubated under physiological conditions, e.g. at about 10, 15, 20, 25, 30, 35-37 degrees C.
- Buffers, such as Tris, etc., and salts may be included in the reaction mix as is known in the art, e.g. including one or more of Na, Mg, and K at concentrations from around 0.1 to 500 mM, and generally including ATP at a concentration of at least about 0.01 mM, more usually at least about 0.1 mM.
- the ligase component enzymes may be included in a reaction mixture as follows:
- the stoichiometry of the reaction may be as follows.
- the ratio of Ku:XRCC4 may range from around about 10:1 to 1:20 to 50:1.
- the ratio of Ku:Cernunnos may range from around about 2:1 to 1:20 to 20:1.
- DNA-PKcs is optionally included, and may range from around about 1:1 to 1:20 to 20:1 with respect to Ku.
- Substrates for ligation may have non-compatible, e.g. 3′ over hang ends, may have compatible ends, blunt ends, or may be single stranded. Usually such substrates have non-compatible ends, and are at least about 10 nucleotides in length, at least about 20 nucleotides in length, at least about 30 nucleotides in length, at least about 100 nucleotides in length, or longer. At least one of the ends to be ligated comprises a 5′ PO 4 .
- the efficiency of ligation for blunt ends is usually around about 50%, around about 75%, around about 90% of the efficiency for ligation of compatible ends in a comparable reaction, or more.
- reaction conditions where from about 1% to about 3% of compatible ends are ligated at least about 0.5%, at least about 1%, or more of blunt ends are joined.
- the efficiency of a blunt end to a 3′ overhang, or a 5′ overhang to a blunt end is around about 5%, around about 7.5%, around about 10% of the efficiency for ligation of compatible ends, or more.
- the efficiency for ligation of compatible ends is around about 5%, around about 7.5%, around about 10% of the efficiency for ligation of compatible ends, or more.
- reaction conditions where from about 1% to about 3% of compatible ends are ligated at least about 0.05%, at least about 0.1%, or more of 3′ overhang, or a 5′ overhang to a blunt end are joined.
- the efficiency of ligation for two 3′ overhangs is around about 5%, around about 7.5% around about 10% of the efficiency for ligation of compatible ends, or more.
- the efficiency of ligation for a 3′ overhang to a 5′ overhang is around about 0.1%, 0.2%, 0.5% of the efficiency for ligation of compatible ends, or more.
- the efficiency for ligation of compatible ends is around about 0.1%, 0.2%, 0.5% of the efficiency for ligation of compatible ends, or more.
- at least about 0.001%, at least about 0.002%, or more of a 3′ overhang to a 5′ overhang are joined.
- Polypeptides Involved in MEnd DNA Ligations include:
- Cernunnos/XLF Cernunnos-XLF is a nonhomologous end-joining factor.
- Genbank e.g. human (CAI99410), cow (XP — 586059), and dog Cernunnos-XLF (XP — 848099), and homologs thereof may be identified in various organisms by methods of sequence comparison, as known in the art. See, for examples, Ahnesorg et al. (2006) Cell. January 27; 124:301-313; Buck et al. (2006) Cell. January 27; 124:287-299; Callebaut et al. (2006) J. Biol. Chem. May 19; 281(20):13857-60, each herein specifically incorporated by reference.
- XRCC4/Ligase4 (XL).
- the DNA Ligase IV complex consisting of the catalytic subunit DNA Ligase IV (Wei et al. (1995) Mol Cell Biol. 15(6):3206-16) and its cofactor XRCC4 (Li et al. (1995) Cell. 83:1079-89, Li and Alt (1996) Curr Top Microbiol Immunol. 217:143-50, each herein specifically incorporated by reference), performs the ligation step of repair.
- DNA ligase IV is conserved in all eukaryotes, and is part of a family of ATP-dependent DNA ligases that are involved in DNA replication, recombination and repair.
- DNA ligases have two common domains: a catalytic domain (CD) that contains several conserved nucleotide-binding motifs, and a conserved non-catalytic domain (NCD).
- CD catalytic domain
- NCD conserved non-catalytic domain
- DNA ligase IV has a long C-terminal extension comprising of two BRCT domains (after the C-terminal domain of a breast cancer susceptibility protein, BRCA1), which are phosphopeptide-binding modules found in many proteins that regulate DNA damage responses, such as BRCA1, MDC1 and BARD1.
- BRCA1 breast cancer susceptibility protein
- a short linker region that is required for the binding of the XRCC4 protein, which is important for ligase activity, connects the two BRCT domains.
- DNA ligase IV is a nuclear enzyme that joins the breaks in the phosphodiester backbone of DNA.
- the reaction mechanism involves the formation of a covalent enzyme-AMP intermediate from the cleavage of ATP to AMP and pyrophosphate.
- the adenylate group from AMP is then transferred to the 5′-phosphate of the nicked DNA molecule.
- the DNA ligase seals the gap by phosphodiester bond formation, via the displacement of the AMP residue with the 3′-hydroxyl group from the adjacent DNA strand.
- Ku The Ku heterodimer, consisting of Ku70 (see Reeves and Sthoeger (1989) J Biol. Chem. 264(9):5047-52) and Ku860 (Mimori et al. (1990) Proc Natl Acad Sci U.S.A. 87(5):1777-81, each herein specifically incorporated by reference).
- the Ku complex functions as the DNA binding component of DNA-dependent protein kinase (DNA-PK).
- Ku binds directly to the termini of DSBs and has end-bridging activity. Ku forms a ring that encircles duplex DNA, cradling two full turns of the DNA molecule.
- Ku acts to structurally support and align the DNA ends, to protect them from degradation, and to prevent promiscuous binding to unbroken DNA.
- Ku effectively aligns the DNA, while still allowing access of polymerases, nucleases and ligases to the broken DNA ends to promote end joining.
- p350 catalytic polypeptide of approximately 350 kD (p350)
- DNA-PKcs is a serine/threonine kinase in the phosphoinositide 3-kinase (PI3K) family that is believed to be a signaling molecule in response to cellular stress.
- DNA-PKcs can phosphorylate several nuclear proteins in vitro, including DNA ligase IV and XRCC4.
- DNA-PK DNA-PKcs (Hartley et al. (1995) Cell. 82(5):849-56, herein specifically incorporated by reference).
- Purified recombinant Ku70/86 heterodimer was produced by co-infecting Sf9 insect cells with baculoviruses containing sequences encoding Ku70-His and Ku86. Infect with limiting amounts of Ku70 virus. Collect cells at about 48 hours post-infection and flash-freeze. Store at ⁇ 80° C.
- lyse cells in lysis buffer of 50 mM Na.PO 4 pH 8.0, 500 mM NaCl, 0.5% Igepal, 10% glycerol, 10 mM B-mercaptoethanol, 1 mM phenylmethanesulfonyl fluoride, 2.7 mM benzamidine, EDTA-free protease inhibitor cocktail tablet [Roche]).
- Sonicate cells Clarify lysate with centrifugation in SS-34 rotor at 15,500 rpm for 30 minutes. Collect supernant. Incubate with Ni-NTA beads in 20 mM imidazole.
- wash buffer 50 mM Na.PO 4 pH 7.4, 500 mM NaCl, 40 mM imidazoles, 0.5% Igepal, 10% glycerol, 10 mM B-ME). Elute with: 50 mM Na.PO 4 pH 7.4, 500 mM NaCl, 300 mM imidaole, 10% glycerol, 10 mM B-mercaptoethanol. Purify over Superose-12 gel filtration column. Elute with: 50 mM Na.PO 4 pH 7.4, 300 mM NaCl, 1 mM EDTA, 10% glycerol, 10 mM B-ME. Flash-freeze proteins and store at ⁇ 80° C.
- Endogenous DNA-PKcs was purified by coupling Ku80C-derived peptide (KGSGEEGGDVDDLLDMI) to 1-ml NHS-activated HiTrap column (GE Healthcare). Dissolve 20 mg of the peptide in 1 ml of coupling buffer. Wash 1 ml of NHS-activated HiTrap resin with coupling buffer. Pour into column and incubate with peptide overnight 4° C. Inject 6 ml of solution A. Inject 6 ml of solution B. Inject 6 ml of solution A. Leave the column overnight at +4° C. Inject 6 ml of solution B. Inject 6 ml of solution A. Inject 6 ml of solution B. Inject 2 ml of storage buffer.
- DNA-PKcs Over Mono Q anion-exchange column. If skipping previous step, dialyze protein into: 50 mM Na.PO 4 pH 7.5, 5 mM EDTA, 100 mM NaCl, 10% glycerol, 20 mM B-MEA. Inject protein onto column. Elute with NaCl gradient: 50 mM Na.PO 4 pH 7.8, 5 mM EDTA, 10% glycerol, 20 mM B-mercapethanol, 50 mM NaCl to 1 M NaCl. Snap-freeze proteins and store at ⁇ 80° C.
- Elution Buffer 50 mM Tris pH 7.4, 0.5 M NaCl, 1 mM EDTA, 10% glycerol, 10 mM ⁇ -ME. Dialyze peak fractions against previous Superdex 200 elution buffer containing 20 mM NaCl. Purify over Mono Q (5/50 GL) anion-exchange column. Elute in same buffer as above with linear NaCl gradient (20-600 mM NaCl). Flash-freeze fractions containing protein and store at ⁇ 80° C.
- Cernunnos purification was as follows: It was expressed in E. Coli . Purified over Ni-NTA beads. Fractions were run over a Superdex-200 gel filtration column. Peak fractions were then run over a HiTrap Heparin column and the purified proteins were stored at ⁇ 80oC.
- 1 ⁇ End-Joining Buffer 25 mM Tris pH 7.5, 75 mM NaCl, 72.5 mM KCl, 2 mM DTT, 50 ⁇ g/ml BSA, 0.025% Triton X-100, 5% Glycerol, 0.1 mM EDTA, 5% PEG MW>8000 kDa.
- NHEJ nonhomologous end-joining pathway
- xenobiotic agents such as topoisomerase II inhibitors and ionizing radiation, or the cellular pathway for V(D)J recombination of the immunoglobulin genes.
- NHEJ processes the ends and repairs the breaks with high efficiency and minimal nucleotide loss.
- ligatable ends such as the blunt signal ends created by V(D)J recombination, NHEJ suppresses processing and repairs the breaks directly.
- NHEJ optimizes the preservation of DNA sequence, but the mechanism is not understood.
- Core proteins for NHEJ include Ku, DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and XRCC4/Ligase IV (XL).
- Ku consists of two subunits, Ku70 and Ku86, binds with high affinity to DNA ends and recruits DNA-PKcs to the ends.
- DNA-PKcs brings the ends together into a synaptic complex and then undergoes activation of its kinase domain to facilitate later steps in the joining reaction.
- XL performs the final ligation step.
- NHEJ utilizes nuclease and polymerase activities to process the ends.
- the exo/endonuclease Artemis interacts with DNA-PKcs. Activation of the DNA-PKcs kinase facilitates Artemis endonuclease activity, which opens the hairpin ends created during V(D)J recombination.
- DNA polymerases mu and lambda interact with Ku and XL in vitro, and add nucleotides to the immunoglobulin light chain and heavy chain junctions, respectively, during V(D)J recombination.
- Cernunnos also stimulated joining of ends with mismatched overhangs by 40 to 150-fold (rows 8-11).
- Ku DNA-PKcs, XL and Cernunnos joined mismatched 5′ overhangs (Acc651-EcoRI, 0.0039%) with 23-fold lower efficiency than mismatched 3′ overhangs (KpnI-SacI, 0.091%).
- Cernunnos facilitated more efficient joining when the 5′ overhangs contained partially complementary sequences (BamHI-EcoRI, 0.25%).
- Cernunnos exhibited a preference for 3′ overhangs over 5′ overhangs. This preference also occurred when we omitted DNA-PKcs from the joining reaction ( FIG. 6 ). The effect of Cernunnos was specific, since Cernunnos had no effect on ligation of blunt ends to 3′ overhangs by bacteriophage T4 DNA ligase ( FIG. 7 ).
- Cernunnos requires Ku to promote mismatched end joining by XL.
- a sub-stoichiometric concentration of Cernunnos 0.05 nM
- stimulated joining by XL 0.5 nM
- DNA-PKcs 5 nM
- a stoichiometric excess of Cernunnos (15 nM) stimulated joining 200-fold, up to a level of nearly 1%.
- Cernunnos promotes preservation of 3′ overhangs.
- 21 of the 22 sequenced junctions retained the 3′ KpnI overhang, while only 1 junction retained the SacI overhang. This preference occurred only in the absence of Cernunnos. In the presence of Cernunnos, the 3′ overhangs were retained with equal probability.
- Cernunnos together with Ku and XRCC4 aligns mismatched ends to promote ligation by Ligase IV. It is shown herein that Cernunnos and Ku stimulated XL to join blunt ends and several types of mismatched ends that are non-complementary or partially complementary ( FIG. 1 ). On the other hand, Cernunnos failed to stimulate joining of ends with cohesive 4 nucleotide overhangs. Thus, Cernunnos may be dispensable for cohesive end joining with 4 nucleotide overhangs, but may provide the necessary alignment for XL to join blunt ends, ends that are less cohesive, or ends with mismatched overhangs.
- MEnd ligase activity from Ku, XL and Cernunnos preserves sequences by direct ligation of the 3′ overhang to the 5′ phosphate of the opposing end.
- MEnd ligase activity for mismatched ends has applications for recombinant DNA technology. For example, sheared genomic DNA and PCR-amplified DNA contain 3′ overhangs generated by the shearing process or by the weak TdT activity of Taq polymerase, respectively. MEnd ligase can ligate such DNA molecules directly into a blunt-ended cloning vector.
- DNA substrates Preparation of DNA substrates.
- End-joining reactions We performed end-joining reactions, purified the DNA products on a QIAquick column (Qiagen), measured joining efficiencies by quantitative PCR, and sequenced the DNA junctions.
- Lysate was loaded onto a Ni-NTA column (Qiagen), and bound proteins were eluted with 250 mM imidazole (100% Buffer A). We then pooled the fractions and subjected them to gel filtration on a Superdex-200 column in 1 M NaCl/20 mM Hepes, pH 8.0/10 mM 2-mercaptoethanol/1 mM EDTA/10% glycerol.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
- In molecular biology, ligases act to create a phosphodiester bond between strands of DNA or RNA. DNA ligase connects broken DNA strands to form covalent phosphodiester bonds between 3′ hydroxyl ends of one nucleotide with the 5′ phosphate end of another, using ATP in the process. The known DNA ligases in mammalian cells include DNA ligase I, which ligates Okazaki fragments during lagging strand DNA replication. DNA ligase III complexes with DNA repair protein XRCC1 to aid in sealing base excision mutations and recombinant fragments, and DNA ligase II is an alternatively spliced form of DNA ligase Ill. DNA ligase IV complexes with XRCC4 and catalyzes the final step in the non-homologous end joining DNA double-strand break repair pathway. It is also required for V(D)J recombination, the process which generates diversity in immunoglobulin and T-cell receptor loci during immune system development.
- DNA ligases have become an indispensable tool in modern molecular biology research for generating recombinant DNA sequences. For example, DNA ligases are used with restriction enzymes to insert DNA fragments, often genes, into plasmids. Common commercially available DNA ligases were originally discovered in bacteriophage T4, E. coli or other bacteria. Using these enzymes, the most efficient way for a ligase to link DNA fragments is to connect two sticky ends together from a restriction digest. The hydrogen bonds between the complementary bases aid ligase in holding the two ends together while the phosphodiester bond is formed.
- DNA double-strand breaks (DSBs) occur at random upon genotoxic stresses and represent obligatory intermediates during physiological DNA rearrangement events such as the V(D)J recombination in the immune system. DSBs, which are among the most toxic DNA lesions, are repaired by either homologous recombination or nonhomologous end joining (NHEJ), preferentially by the nonhomologous end-joining (NHEJ) pathway in higher eukaryotes. Failure to properly repair DSBs results in genetic instability, developmental delay, and various forms of immunodeficiency. Repair of DNA double strand breaks (DSB) by the nonhomologous end-joining pathway in mammals requires at least seven proteins involved in a simplified two-step process: (i) recognition and synapsis of the DNA ends dependent on the DNA-dependent protein kinase (DNA-PK) formed by the Ku70/Ku80 heterodimer and the catalytic subunit DNA-PKcs in association with Artemis; (ii) ligation dependent on the DNA ligase IV.XRCC4.Cernunnos-XLF complex (Drouet et al. (2006) J Biol. Chem. 281(38):27784-93).
- It has been reported that T4 DNA ligase, unlike Escherichia coli DNA ligase, Taq DNA ligase and Ampligase, is able to join the ends of single-stranded DNA in the absence of any duplex DNA structure at the ligation site. However, such nontemplated ligation of DNA oligomers catalyzed by T4 DNA ligase occurs with a very low yield, and thus is insignificant in many molecular biological applications of T4 DNA ligase.
- DNA ligase enzymes are of commercial interest for catalysis of a variety reactions. The present invention provides a useful complex that acts as a single-strand DNA ligase.
- The present invention relates to a mismatched end DNA ligase. Conventional ligases join both strands of two DNA ends. The ends must be compatible, consisting of either two blunt ends, or two ends with overhanging single strands that are complementary to each other. By contrast, the mismatched end DNA ligase of the invention will act on noncompatible DNA ends, ligating two single strands to each other even if the other two single strands are not compatible, thus the term “Mis-matched End (MEnd) DNA ligase”.
- In one embodiment, a purified polypeptide composition is provided, where multiple polypeptides coordinate to catalyze ligation of mismatched DNA strands at high efficiency. Such a group of polypeptides may be referred to as a complex or association, although the term does not, in this context, imply direct molecular interaction between the different polypeptides. In one such embodiment, the polypeptides are eukaryotic proteins, e.g. proteins from animals, including mammals.
- In one such embodiment, the polypeptides of the association are Ku, Cernunnos, and XRCC4/Ligase4 (XL). This association can ligate DNA ends with a 3′ overhang to a recessed 5′ end, to a blunt end, or to a compatible end. The ligation efficiency of noncompatible ends is from around 10% of that seen for compatible ends. In another embodiment, the proteins are Ku, Cernunnos, XRCC4/Ligase4 (XL) and DNA-PK.
- In another embodiment, the invention relates to an in vitro method of ligating nucleotides or nucleotide analogs or nucleic acids containing nucleotides or nucleotide analogs, comprising contacting polynucleotides or nucleic acids with polypeptides of the invention, wherein the ligase catalyzes a reaction of ligation of the nucleotides, nucleotide analogs or nucleic acids. The polynucleotides used in the methods of the invention may be RNA or DNA, including single-stranded RNA or DNA. The nucleotide analogs may contain modified bases, modified sugars and/or modified phosphate groups.
- In another embodiment, a method is provided to screen candidate agents, e.g. polypeptides and associations thereof, for mis-matched end DNA ligase activity. In such methods, a candidate agent is contacted with polynucleotides in a joining reaction. The polynucleotide substrate preferably has non-compatible ends. The efficiency of ligation may be assessed by various criteria, e.g. by PCR, using primers that amplify on ligated ends. The ability of a candidate agent to catalyze mis-matched end DNA ligation is evidenced by the ability to join mis-matched ends.
- The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings.
-
FIGS. 1A-B . Cernunnos stimulates joining of mismatched DNA ends. (A) Purification of NHEJ proteins. Commassie staining after SDS-PAGE shows our purified preparations of Ku, DNA-PKcs (Pk), Cernunnos (C), and XRCC4/Ligase IV (XL). (B) Cernunnos stimulates joining of non-cohesive ends by Ku, DNA-PKcs and XL. Linear DNA substrates were incubated with no protein (dark gray bars), Ku, DNA-PKcs and XL (light gray bars), or Ku, DNA-PKcs, XL and Cernunnos (black bars). The orientation of DNA is depicted in the upper left corner. We tested compatible ends (rows 1-3) with cohesive 5′ overhangs (EcoRI-EcoRI), cohesive 3′ overhangs (KpnI-KpnI), or blunt ends (EcoRV-EcoRV). We also tested 8 combinations of mismatched ends (rows 4-11). Note that SacII creates a 2nucleotide 3′ overhang. All other 3′ and 5′ overhangs were 4 nucleotides. The lower right panels show the overhangs from the KpnI-SacI, Acc651-EcoRI and EcoRI-BamHI ends. We measured joining efficiency by quantitative PCR and expressed efficiency as percentage of input DNA ends joined. Because of differences among experiments, we plotted joining efficiency on a logarithmic scale. Concentrations of Ku, DNA-PKcs, XL and Cernunnos were 5 nM, 5 nM, 0.5 nM and 2.5 nM respectively, in this figure and in all other figures unless otherwise noted. -
FIGS. 2A-B . Ku, DNA-PKcs, XL and Cernunnos act in concert to join mismatched 3′ overhangs. (A) Cernunnos stimulates joining of mismatched ends by Ku, DNA-PKcs and XL, but not by XL alone. DNA substrates with mismatched 3′-3′ overhangs (KpnI-SacI) were incubated with XL alone or XL, Ku and DNA-PKcs (Pk). Concentrations of Ku, DNA-PKcs and XL were 5 nM, 5 nM and 0.5 nM, respectively. Cernunnos (C) was added at concentrations of: 0.05 nM, 0.1 nM, 0.5 nM, 2.5 nM, 5 nM and 15 nM. The point in the lower left shows the background PCR signal in the absence of protein. Error bars represent the variation in duplicate measurements. (B) Cernunnos requires Ku to promote mismatched end joining by XL. DNA substrates with mismatched 3′ overhangs (KpnI-SacI) were incubated with different combinations of the core NHEJ proteins Ku, DNA-PKcs, XL and Cernunnos (2.5 nM). -
FIG. 3 . Cernunnos promotes retention of overhanging ends. We incubated DNA substrates with Ku, DNA-PKcs and XL, with or without the addition of Cernunnos. The DNA substrates had mismatched 3′-3′ ends (KpnI-SacI); blunt-3′ ends with 4 nucleotide overhangs (EcoRV-KpnI); or blunt-3′ ends with 2 nucleotide overhangs (EcoRV-SacII). We used quantitative PCR to measure the percentage of DNA ends joined and sequenced products from each reaction to characterize the junctions. The legend at the top of the figure indicates how the data are presented for each reaction. The junctions recovered from PCR amplification are depicted to show nucleotide addition (black background) and nucleotide deletion (white background). -
FIG. 4 . Ku, XL and Cernunnos join mismatched ends using the 5′ phosphate from only one end. To determine how Ku, XL and Cernunnos joined mismatched ends, we treated the EcoRV and KpnI substrates with DNA phosphatase (Antarctic phosphatase, NEB). EcoRV* and KpnI* denote dephosphorylated DNA molecules. We confirmed successful removal of the 5′-phosphates by incubating each DNA preparation with T4 ligase, and demonstrating loss of more than 90% of the ligation products by agarose gel electrophoresis. We incubated mismatched DNA substrates (EcoRV-KpnI, EcoRV-KpnI*, EcoRV*-KpnI or EcoRV*-KpnI*) with Ku, XL (1 nM) and Cernunnos (2 nM), with or without DNA-PKcs, amplified the junctions by quantitative PCR, and plotted joining efficiency on a linear scale. -
FIGS. 5A-D . Ku, XL and Cernunnos join mismatched ends by ligation of one strand. (A) Schematic of the gel-based assay for joining. We incubated Ku, XL and Cernunnos (Ku/XL/C) or T4 ligase (T4) with a linear DNA substrate containing EcoRI-EcoRI, EcoRV-EcoRV or EcoRV-KpnI ends, digested the DNA products with XmnI, and used T4 polynucleotide kinase to radiolabel the DNA. Concentrations of XL and Cernunnos were 1 nM and 5 nM, respectively. For EcoRV-EcoRV and EcoRV-KpnI ends, we performed a second digest with ApoI or MspA1I to remove radiolabel from one DNA strand. To confirm that ligation created a new phosphodiester bond, we digested the products of the EcoRV-EcoRV joining reaction with EcoRV. The figure depicts radiolabeled DNA strands in red with red asterisks at the 5′ end, and unlabeled DNA strands in black. DNA products were resolved by denaturing gel electrophoresis. (B) Ku, XL and Cernunnos joined cohesive EcoRI-EcoRI ends. Ku, XL and Cernunnos (lane 3) and T4 ligase (lane 4) produced a higher molecular weight band of 498 nucleotides (nt). The molecular weight markers consisted of a radiolabeled 50 bp ladder (lane 1). Joining efficiencies for Ku/XL/C and T4 (calculated from the ratio of intensities in the 498 nt band to the 339 nt band) were 39% and 89%, respectively. Sizes of the ligated higher molecular weight bands in (B), (C) and (D) appear in blue typeface. (C) Ku, XL and Cernunnos joined blunt EcoRV-EcoRV ends. Ku, XL and Cernunnos (lane 3) and T4 ligase (lane 4) produced a higher molecular weight band of 470 nt, with joining efficiencies of 20% and 14%, respectively. ApoI digestion converted the 470 nt band to 413 nt and 57 nt bands, and converted the 281 nt band to 224 nt and 57 nt bands (lane 6). MspA1I digestion converted the 470 nt band to 434 nt and 36 nt bands, and the 189 nt band to 153 nt and 36 nt bands (lane 8). Intensities of the 413 nt and 434 nt bands were reduced to 50% of the 470 nt band because the second digestion removed the radiolabel from one strand. EcoRV digestion eliminated the 470 nt band (lane 10), demonstrating that the DNA junction contained new phosphodiester bonds. The 153 nt, 57 nt and 36 nt bands are not shown. (D) Ku, XL and Cernunnos joined only one strand from mismatched EcoRV-KpnI ends. Ku, XL and Cernunnos (lane 3) produced a higher molecular weight band of 472 nt, with a joining efficiency of 5%. ApoI digestion converted the 472 nt band to 415 nt and 57 nt bands, and the 281 nt band to 224 nt and 57 nt bands (lane 5). The intensities of the 472 nt and 415 nt bands were equivalent (lanes 3 and 5). MspA1I digestion converted the 472 nt band to a 36 nt band, and converted the 191 nt band to a 36 nt band (lane 7), demonstrating ligation of only one strand. -
FIG. 6 . Addition of Cernunnos to Ku and XL promotes the retention of 3′ overhangs. We incubated DNA substrates with Ku and XL, with or without Cernunnos. The DNA substrates had mismatched blunt-3′ ends with four nucleotide overhangs (EcoRV-KpnI) or blunt-3′ ends with two nucleotide overhangs (EcoRVSacII). The junctions recovered from PCR amplification are depicted to show nucleotide addition (black background) and nucleotide deletion (white background). -
FIG. 7 . Addition of Cernunnos weakly promotes retention of 5′ overhangs. DNA substrates for joining were mismatched blunt-5′ ends EcoRV-BamHI (Upper) or EcoRV-EcoRI (Lower). We tested the effect of adding Cernunnos to Ku, DNA-PKcs, and XL (Left) or to Ku and XL (Right). We observed increased retention of 5′ overhangs for EcoRV-BamHI ends (P=0.0002), but not for EcoRV-EcoRI ends (P=0.47). -
FIG. 8 . Ku, DNA-PKcs, XL, and Cernunnos preparations lack detectable exonuclease activity. We labeled the 5′ end of a 32-nt single-stranded DNA fragment with [g-32P]ATP and T4 polynucleotide kinase, and then incubated the DNA (0.5 mM) with different combinations of purified Ku (1.25 pmol), DNA-PKcs (1.25 pmol), XL (0.25 pmol), and Cernunnos (2.5 pmol) in a total volume of 10 ml at 37° C. for 30 min in 25 mM Tris (pH 8.0), 50 mM NaCl, 10 mM MgCl2, 1 mM DTT, and 50 ng/ml of BSA (lanes 3-10). As a positive control for nuclease activity, we incubated the DNA with Klenow fragment (0.2 unit), which contains a 3′-5′ exonuclease activity, at room temperature for 45 min (lane 2). We stopped reactions by adding formamide gel loading buffer and heating at 95° C. for 2 min, resolved the DNA products on a 10% denaturing polyacrylamide gel, dried the gel, and analyzed the gel with Phosphorimager analysis (Molecular Dynamics) and ImageQuant quantitation software. - Polypeptides are provided that provides for efficient ligation of noncompatible DNA ends. An association of polypeptides is shown herein to provide for ligase activity that will act on noncompatible DNA ends. In one embodiment, purified polypeptides are provided, where the association of the polypeptides in a reaction mixture catalyzes ligation of DNA single strands at high efficiency. The polypeptides may include Ku, Cernunnos, and XRCC4/Ligase4 (XL) and optionally DNA-PK.
- In another embodiment, the invention relates to a method of ligating nucleotides or nucleotide analogs or nucleic acids containing nucleotides or nucleotide analogs, comprising contacting polynucleotides or nucleic acids with the polypeptides of the invention, wherein the ligase catalyzes a ligation reaction of the nucleotides, nucleotide analogs or nucleic acids. The polynucleotides used in the methods of the invention may be RNA or DNA, including single-stranded RNA or DNA. The nucleotide analogs may contain modified bases, modified sugars and/or modified phosphate groups.
- Reactions of interest are performed in vitro, and join polynucleotides that have noncompatible ends, i.e. the terminus of one polynucleotide does not base pair with the terminus of the polynucleotide to be joined. Reactions of interest include reactions where a blunt terminus is joined to a blunt terminus; where a blunt terminus is joined to a 5′ overhang, where a blunt terminus is joined to a 3′ overhang, where two 5′ overhangs are joined, where two 3′ overhangs are joined, or where single stranded molecules are joined. In general at least one terminus will comprise a 5′ phosphate group. Where 3′ overhangs are ligated, the sequence of one of the overhangs is maintained. By the
term 5′ overhang, or 3′ overhang, reference is made to a double stranded polynucleotide where the terminus comprises a single stranded region of at least one nucleotide, which may comprise 2, 3, 4, 5, or more nucleotides in a single stranded conformation, where the terminal nucleotide may be in a 3′ orientation or a 5′ orientation. A blunt terminus comprises no single stranded regions. - Before the present invention is further described, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
- Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
- Methods recited herein may be carried out in any order of the recited events which is logically possible, as well as the recited order of events.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described.
- All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.
- It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
- The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
- Single-strand DNA ligase activity permits construction of recombinant DNA molecules without the usual limitation of compatible ends imposed by conventional ligases. Methods of use for the MEnd DNA ligase include, without limitation:
- Cloning of PCR-amplified DNA. During PCR amplification of DNA, Taq polymerase often catalyzes the non-templated addition of one or two bases, creating a 3′ overhang. Thus, PCR products are not blunt-ended and cloning efficiency is compromised by the need to use specialized cloning vectors. The MEnd single-strand DNA ligase will permit these fragments to be ligated directly into a blunt-ended cloning vector.
- Random cloning of genomic DNA. Current technologies for fragmenting genomic DNA leave ends with protruding single strands. If DNA polymerase is used to convert protruding 5′ overhangs into blunt ends, the genomic DNA fragments will have blunt ends and protruding 3′ overhangs. The MEnd single-strand DNA ligase will ligate these fragments directly onto a cloning vector.
- Cloning of full-length cDNA. Currently, there is no reliable method for cloning full-length cDNA from mRNA. Second strand DNA synthesis requires priming for polymerization that fails to copy sequences at the 3′ end of the cDNA. Single-strand DNA ligase activity overcomes this difficulty. Using random hexamers as primers for second strand synthesis, single-strand DNA ligase will ligate the protruding 3′ overhang directly into a cloning vector.
- The MEnd DNA ligase of the invention is comprised of an association of polypeptides. The association is not required to be pre-assembled, it is sufficient to add the individual polypeptides in a reaction mixture, e.g. in the presence of polynucleotides to be ligated. In a preferred embodiment, one or more, or all of the polypeptides are purified prior to addition into a reaction mixture.
- In some embodiments of the invention, a kit is provided for ligation, where the kit comprises at least the polypeptides Ku, Cernunnos, and XRCC4/Ligase4 (XL) and optionally comprises DNA-PK. One, two, three or all the polypeptides may be provided in a purified form. The polypeptides may be derived from any source, e.g. bacterial eukaryotic, etc. In some embodiments the polypeptides are derived from an animal source, e.g. from a mammalian source. The kit may further comprise a positive control mixture of nucleotides for ligation. The kit may further comprise buffer suitable for the reaction, for example provided as a concentrate, i.e. 10×, 100×, and the like.
- The enzymes of the invention may be “isolated”; as used herein, an “isolated” polypeptide has been completely or partially purified from other polypeptides. For example, an isolated polypeptide of the invention may be substantially isolated with respect to the complex cellular milieu in which it naturally occurs. In some instances, the isolated material will form part of a composition (for example, a crude extract containing other substances), buffer system or reagent mix. In other circumstance, the polypeptide may be purified to essential homogeneity, for example as determined by PAGE or column chromatography such as HPLC. Thus, an isolated polypeptide can include a polypeptide that is synthesized chemically or by recombinant means.
- The present invention also pertains to polypeptide sequences that are not necessarily found in nature but that have substantially similar activity to the polypeptides described below. The invention also encompasses variations of the polypeptide sequences of the molecules providing for DNA ligase activity, such as those encoding active fragments or active derivatives of the polypeptides. Such variations can be naturally-occurring, or non-naturally-occurring, such as those induced by various mutagens and mutagenic processes. Intended variations include, but are not limited to, addition, deletion and substitution of one or more amino acids that result in conservative or non-conservative amino acid changes, including additions and deletions; however, such alterations should preserve at least one activity of the polypeptide, i.e., the altered or mutant polypeptide should be an active derivative of the naturally-occurring polypeptide. For example, the mutation(s) can preferably preserve the three dimensional configuration of the binding site of the native polypeptide, or can preferably preserve the activity of the polypeptide (e.g., if the polypeptide is a DNA ligase, any mutations preferably preserve the ability of the enzyme to catalyze ligation of two polynucleotide strands). The presence or absence of activity or activities of the polypeptide can be determined by various standard functional assays including, but not limited to, assays for binding activity or enzymatic activity.
- The methods of the invention may utilize polypeptide sequences that have a substantial identity with the polypeptide sequences of known Ku, Cernunnos, XRCC4/Ligase4 (XL) and DNA-PK sequences, for example having at least about 10%, preferably at least about 20%, more preferably at least about 30%, more preferably at least about 40%, even more preferably at least about 50%, yet more preferably at least about 70%, still more preferably at least about 80%, and even more preferably at least about 90% identity, and still more preferably 95% identity, and providing for a molecule having at least about 10%, preferably at least about 20%, more preferably at least about 30%, more preferably at least about 40%, even more preferably at least about 50%, yet more preferably at least about 70%, still more preferably at least about 80%, and even more preferably at least about 90% of the activity of the molecules exemplified herein. Variant and derivative sequences may include substantial regions of sequence identity, e.g. of at least about 50 contiguous amino acids identity, at least about 100 contiguous amino acids identity, at least about 150 contiguous amino acids identity, at least about 200 contiguous amino acids identity. Fragments may comprise at least about 50 contiguous amino acids, at least about 100 contiguous amino acids, at least about 150 contiguous amino acids, at least about 200 contiguous amino acids or more. An “active fragment,” as referred to herein, is a portion of polypeptide (or a portion of an active derivative) that retains the polypeptide's activity, as described above.
- Appropriate amino acid alterations can be made on the basis of several criteria, including hydrophobicity, basic or acidic character, charge, polarity, size, the presence or absence of a functional group (e.g., —SH or a glycosylation site), and aromatic character. Assignment of various amino adds to similar groups based on the properties above will be readily apparent to the skilled artisan; further appropriate amino acid changes can also be found in Bowie et al. (1990), Science, 247:1306-1310 (1990). For example, conservative amino acid replacements can be those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids are generally divided into four families: (1) acidic=aspartate, glutamate; (2) basic=lysine, arginine, histidine; (3) nonpolar=alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar=glycine, asparagine, glutamine, cystine, serine, threonine, tyrosine. Phenylalanine, tryptophan and tyrosine are sometimes classified jointly as aromatic amino acids. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine or a similar conservative replacement of an amino add with a structurally related amino acid will not have a major effect on activity or functionality.
- The polypeptides of the invention can also be fusion polypeptides comprising all or a portion (e.g., an active fragment) of the native polypeptide amino acid sequence fused to an additional component, with optional linker sequences. Additional components, such as radioisotopes and antigenic tags, can be selected to assist in the isolation or purification of the polypeptide or to extend the half life of the polypeptide; for example, a hexahistidine tag would permit ready purification by nickel chromatography. The fusion protein can contain, e.g., a glutathione-S-transferase (GST), thioredoxin (TRX) or maltose binding protein (MBP) component to facilitate purification; kits for expression and purification of such fusion proteins are commercially available. The polypeptides of the invention can also be tagged with an epitope and subsequently purified using antibody specific to the epitope using art recognized methods.
- Polypeptides described herein can be isolated from naturally-occurring sources (e.g., isolated from host cells). Alternatively, the polypeptides can be chemically synthesized or recombinantly produced. For example, PCR primers can be designed to amplify the ORFs from the start codon to stop codon. The primers can contain suitable restriction sites for an efficient cloning into a suitable expression vector. The PCR product can be digested with the appropriate restriction enzyme and ligated between the corresponding restriction sites in the vector (the same restriction sites, or restriction sites producing the same cohesive ends or blunt end restriction sites).
- The polypeptides of the present invention can be isolated or purified (e.g., to homogeneity) from cell culture (e.g., from culture of host cells infected with expression vector(s)) by a variety of processes. These include, but are not limited to, anion or cation exchange chromatography, ethanol precipitation, affinity chromatography and high performance liquid chromatography (HPLC). The particular method used will depend upon the properties of the polypeptide; appropriate methods will be readily apparent to those skilled in the art. For example, with respect to protein or polypeptide identification, bands identified by gel analysis can be isolated and purified by HPLC, and the resulting purified protein can be sequenced. The protein can be isolated by conventional means of protein biochemistry and purification to obtain a substantially pure product, i.e., 80, 95 or 99% free of cell component contaminants, as described in Jacoby, Methods in Enzymology, Volume 104, Academic Press, New York (1984); Scopes, Protein Purification, Principles and Practice, 2nd Edition, Springer-Verlag, New York (1987); and Deutscher (ed.), Guide to Protein Purification, Methods in Enzymology, Vol. 182 (1990).
- MEnd DNA ligase polypeptides, as described herein can be used in a similar manner as other DNA ligases. In a typical reaction, the polynucleotides to be ligated are combined in a reaction mixture in vitro in the presence of an appropriate buffer, as exemplified in the Examples, ATP, and the polypeptides of the invention. As described herein, it is not necessary for the enzymes to have compatible ends. The reaction mixture is incubated for a period of time sufficient to allow for the desired level of ligation, e.g. for about 10, 30, 60 minutes or more. The polynucleotide substrate may be present at a concentration of from around 0.01 μM to around 100 mM, depending on the specific reaction, where smaller fragments may be present at a high molarity than larger fragments. The reaction is typically incubated under physiological conditions, e.g. at about 10, 15, 20, 25, 30, 35-37 degrees C. Buffers, such as Tris, etc., and salts may be included in the reaction mix as is known in the art, e.g. including one or more of Na, Mg, and K at concentrations from around 0.1 to 500 mM, and generally including ATP at a concentration of at least about 0.01 mM, more usually at least about 0.1 mM.
- The ligase component enzymes may be included in a reaction mixture as follows:
-
- (A) Ku at a concentration of at least about 0.1 mM, at least about 1 mM, at least about 2.5 mM, or more, usually not more than about 50 mM.
- (B) XRCC4/Ligase IV at a concentration of at least about 0.01 mM, at least about 0.1 mM, at least about 0.25 mM, or more, usually not more than about 50 mM.
- (C) Cernunnos/XLF at a concentration of at least about 0.05 mM, at least about 0.1 mM, at least about 1 mM, or more, usually not more than about 50 mM.
- (D) DNA-PKcs is optionally included at a concentration of at least about 0.1 mM, at least about 1 mM, at least about 2.5 mM, or more, usually not more than about 50 mM.
- The stoichiometry of the reaction may be as follows. The ratio of Ku:XRCC4 may range from around about 10:1 to 1:20 to 50:1. The ratio of Ku:Cernunnos may range from around about 2:1 to 1:20 to 20:1. DNA-PKcs is optionally included, and may range from around about 1:1 to 1:20 to 20:1 with respect to Ku.
- Substrates for ligation may have non-compatible, e.g. 3′ over hang ends, may have compatible ends, blunt ends, or may be single stranded. Usually such substrates have non-compatible ends, and are at least about 10 nucleotides in length, at least about 20 nucleotides in length, at least about 30 nucleotides in length, at least about 100 nucleotides in length, or longer. At least one of the ends to be ligated comprises a 5′ PO4.
- The efficiency of ligation for blunt ends is usually around about 50%, around about 75%, around about 90% of the efficiency for ligation of compatible ends in a comparable reaction, or more. For example, in reaction conditions where from about 1% to about 3% of compatible ends are ligated, at least about 0.5%, at least about 1%, or more of blunt ends are joined.
- The efficiency of a blunt end to a 3′ overhang, or a 5′ overhang to a blunt end, is around about 5%, around about 7.5%, around about 10% of the efficiency for ligation of compatible ends, or more. For example, in reaction conditions where from about 1% to about 3% of compatible ends are ligated, at least about 0.05%, at least about 0.1%, or more of 3′ overhang, or a 5′ overhang to a blunt end are joined.
- The efficiency of ligation for two 3′ overhangs is around about 5%, around about 7.5% around about 10% of the efficiency for ligation of compatible ends, or more.
- The efficiency of ligation for a 3′ overhang to a 5′ overhang is around about 0.1%, 0.2%, 0.5% of the efficiency for ligation of compatible ends, or more. For example, in reaction conditions where from about 1% to about 3% of compatible ends are ligated, at least about 0.001%, at least about 0.002%, or more of a 3′ overhang to a 5′ overhang are joined.
- Cernunnos/XLF. Cernunnos-XLF is a nonhomologous end-joining factor. The sequence of various homologs may be accessed at Genbank, e.g. human (CAI99410), cow (XP—586059), and dog Cernunnos-XLF (XP—848099), and homologs thereof may be identified in various organisms by methods of sequence comparison, as known in the art. See, for examples, Ahnesorg et al. (2006) Cell. January 27; 124:301-313; Buck et al. (2006) Cell. January 27; 124:287-299; Callebaut et al. (2006) J. Biol. Chem. May 19; 281(20):13857-60, each herein specifically incorporated by reference.
- XRCC4/Ligase4 (XL). The DNA Ligase IV complex, consisting of the catalytic subunit DNA Ligase IV (Wei et al. (1995) Mol Cell Biol. 15(6):3206-16) and its cofactor XRCC4 (Li et al. (1995) Cell. 83:1079-89, Li and Alt (1996) Curr Top Microbiol Immunol. 217:143-50, each herein specifically incorporated by reference), performs the ligation step of repair. DNA ligase IV is conserved in all eukaryotes, and is part of a family of ATP-dependent DNA ligases that are involved in DNA replication, recombination and repair. These DNA ligases have two common domains: a catalytic domain (CD) that contains several conserved nucleotide-binding motifs, and a conserved non-catalytic domain (NCD). In addition, DNA ligase IV has a long C-terminal extension comprising of two BRCT domains (after the C-terminal domain of a breast cancer susceptibility protein, BRCA1), which are phosphopeptide-binding modules found in many proteins that regulate DNA damage responses, such as BRCA1, MDC1 and BARD1. A short linker region that is required for the binding of the XRCC4 protein, which is important for ligase activity, connects the two BRCT domains. DNA ligase IV is a nuclear enzyme that joins the breaks in the phosphodiester backbone of DNA. The reaction mechanism involves the formation of a covalent enzyme-AMP intermediate from the cleavage of ATP to AMP and pyrophosphate. The adenylate group from AMP is then transferred to the 5′-phosphate of the nicked DNA molecule. Finally, the DNA ligase seals the gap by phosphodiester bond formation, via the displacement of the AMP residue with the 3′-hydroxyl group from the adjacent DNA strand.
- Ku. The Ku heterodimer, consisting of Ku70 (see Reeves and Sthoeger (1989) J Biol. Chem. 264(9):5047-52) and Ku860 (Mimori et al. (1990) Proc Natl Acad Sci U.S.A. 87(5):1777-81, each herein specifically incorporated by reference). The Ku complex functions as the DNA binding component of DNA-dependent protein kinase (DNA-PK). Ku binds directly to the termini of DSBs and has end-bridging activity. Ku forms a ring that encircles duplex DNA, cradling two full turns of the DNA molecule. By forming a bridge between the broken DNA ends, Ku acts to structurally support and align the DNA ends, to protect them from degradation, and to prevent promiscuous binding to unbroken DNA. Ku effectively aligns the DNA, while still allowing access of polymerases, nucleases and ligases to the broken DNA ends to promote end joining. Once Ku is in place, it recruits the catalytic subunit of DNA-PK, a large catalytic polypeptide of approximately 350 kD (p350), which becomes activated when it associates with DNA-bound Ku. DNA-PKcs is a serine/threonine kinase in the phosphoinositide 3-kinase (PI3K) family that is believed to be a signaling molecule in response to cellular stress. DNA-PKcs can phosphorylate several nuclear proteins in vitro, including DNA ligase IV and XRCC4.
- DNA-PK. DNA-PKcs (Hartley et al. (1995) Cell. 82(5):849-56, herein specifically incorporated by reference).
- While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
- It was discovered that the proteins, Ku, Cernunnos, and XRCC4/Ligase4 (XL) could ligate DNA ends with
noncompatible 3′ overhangs. The DNA junctions always contained sequences in which one of the 3′ overhangs was preserved. Thus, the protein complex ligated a 3′ overhang to a recessed 5′ end, displaying a single-strand DNA ligase activity. Additional experiments demonstrated that the complex could ligate an end with a 3′ overhang to a blunt end or ligate two compatible ends. The ligation of noncompatible ends was 10% to 15% of that seen for compatible ends. DNA-PK boosts joining efficiency about 6-fold, but is not required. Upon addition of DNA-PK, ligation of noncompatible ends approached the efficiency seen for compatible ends. - Purified recombinant Ku70/86 heterodimer was produced by co-infecting Sf9 insect cells with baculoviruses containing sequences encoding Ku70-His and Ku86. Infect with limiting amounts of Ku70 virus. Collect cells at about 48 hours post-infection and flash-freeze. Store at −80° C. For purification, lyse cells in lysis buffer of 50 mM Na.PO4 pH 8.0, 500 mM NaCl, 0.5% Igepal, 10% glycerol, 10 mM B-mercaptoethanol, 1 mM phenylmethanesulfonyl fluoride, 2.7 mM benzamidine, EDTA-free protease inhibitor cocktail tablet [Roche]). Sonicate cells. Clarify lysate with centrifugation in SS-34 rotor at 15,500 rpm for 30 minutes. Collect supernant. Incubate with Ni-NTA beads in 20 mM imidazole.
Wash 3× with wash buffer: 50 mM Na.PO4 pH 7.4, 500 mM NaCl, 40 mM imidazoles, 0.5% Igepal, 10% glycerol, 10 mM B-ME). Elute with: 50 mM Na.PO4 pH 7.4, 500 mM NaCl, 300 mM imidaole, 10% glycerol, 10 mM B-mercaptoethanol. Purify over Superose-12 gel filtration column. Elute with: 50 mM Na.PO4 pH 7.4, 300 mM NaCl, 1 mM EDTA, 10% glycerol, 10 mM B-ME. Flash-freeze proteins and store at −80° C. - Endogenous DNA-PKcs was purified by coupling Ku80C-derived peptide (KGSGEEGGDVDDLLDMI) to 1-ml NHS-activated HiTrap column (GE Healthcare). Dissolve 20 mg of the peptide in 1 ml of coupling buffer.
Wash 1 ml of NHS-activated HiTrap resin with coupling buffer. Pour into column and incubate with peptide overnight 4° C. Inject 6 ml of solution A. Inject 6 ml of solution B. Inject 6 ml of solution A. Leave the column overnight at +4° C. Inject 6 ml of solution B. Inject 6 ml of solution A. Inject 6 ml of solution B. Inject 2 ml of storage buffer. Coupling Buffer: 0.2 M NaHCO3 pH=8.3, 0.5 M NaCl; Solution A: 0.5 M 2-aminoethanol, 0.5 M NaCl, pH=8.3; Solution B: 0.5 M NaCl, pH=4; Storage Buffer: 0.05 M Na2HPO4, 0.1% NaN3, pH=7. - Prepare nuclear extracts from 10 L HeLa cells (ordered from National Cell Culture Center). Thaw cells. Resuspend in 4 packed cell volumes of hypotonic lysis buffer: 10 mM KCl, 10 mM Tris-HCl, pH 7.9, 1 mM DTT, Protease Inhibitors. Incubate for 10 minutes on ice. Lyse by Dounce homogenization (Type B pestle). Collect cell nuclei by centrifugation (3,300×g) for 15 min. (SS-34: 5300 rpm). Wash pellet in same buffer as above. Centrifuge 3,300×g for 15 min. Resuspend pellet in 4 packed cell volumes of high salt buffer: 50 mM Tris-HCl, pH 7.9, 0.42 M KCl, 5 mM MgCl2, 0.1 mM EDTA, 20% glycerol, 10% sucrose, 2 mM DTT, Protease inhibitors (5.7 ml 70% sucrose+34.3 ml buffer+80 ul 1M DTT+P/B). Stir nuclei for 30 minutes on ice. Centrifuge for 30 minutes at 26,500×g. Collect supernatant. (Ti-70: 19,000 rpm). Precipitate proteins by adding 0.33 g/ml (NH4)2SO4. Centrifuge for 10 minutes at 20,500×g. (Ti-70: 16,700) Collect pellet. Resuspend pellet in buffer (1.5 ml/L original cell culture): 50 mM Tris-HCl, pH 7.9, 0.1 M KCl, 12.5 mM MgCl2, 1 mM EDTA, 20% glycerol, 1 mM DTT, Protease inhibitors. Dialyze sample overnight against same buffer. (˜50 volumes). Centrifuge for 10 minutes at 9,000×g. Collect supernatant.
- Run NHS-activated HiTrap chromatography. Mix the extract with equal volume of 0.2 M NaCl chromatography buffer A. The final salt concentration should now be approx. 150 mM. Incubate extract with Ku80C-conjugated NHS-activated resin. Tumble overnight at 4° C. Spin the column material down at 2000 rpm, 3 min. Prepare 1 ml Pharmacia column for the chromatography on AKTA FPLC. Chromatography program: 0.05 ml/min, 10
ml 5% (50) mM buffer B, linear gradient from 5% to 100% buffer B in 6 ml, 6 ml at 100% buffer B, 10 ml at 5% buffer B, collect 200 μl fractions. - Chromatography Buffer A: 25 mM HEPES-KOH, pH=7.5, 0.1 mM EDTA, 10% glycerol, 15% maltose, 10 mM B-mercaptoethanol
Chromatography Buffer B: 25 mM HEPES-KOH, pH=7.5, 1 M NaCl, 0.1 mM EDTA, 10% glycerol, 15% maltose, 10 mM B-mercaptoethanol - Purify DNA-PKcs over Superose-6 Gel Filtration Column. Pool less pure fractions and inject into column. Elute in: 50 mM Na.PO4 pH 7.5, 5 mM EDTA, 100 mM NaCl, 10% glycerol, 20 mM B-mercaptoethanol.
- Purify DNA-PKcs over Mono Q anion-exchange column. If skipping previous step, dialyze protein into: 50 mM Na.PO4 pH 7.5, 5 mM EDTA, 100 mM NaCl, 10% glycerol, 20 mM B-MEA. Inject protein onto column. Elute with NaCl gradient: 50 mM Na.PO4 pH 7.8, 5 mM EDTA, 10% glycerol, 20 mM B-mercapethanol, 50 mM NaCl to 1 M NaCl. Snap-freeze proteins and store at −80° C.
- Co-infect insect Sf9 cells with baculoviruses containing XRCC4 and LigaseIV-His. Use limiting amounts LigaseIV-His virus. Harvest cells by centrifugation about 50 hours post-infection Flash-freeze and store −80° C. Lyse cells in lysis buffer: 20 mM Na.PO4 pH 7.4, 0.5 M NaCl, 10 mM imidazoles, 1% IGEPAL-CA630, 5 mM β-mercaptoethanol, 1 mM phenylmethanesulfonyl fluoride, 2.7 mM benzamidine, EDTA-free protease inhibitor cocktail tablet [Roche]). Sonicate cells. Clear lysate by centrifugation at 100,000×g for 1 h in TI-70 rotor. Mix supernatant with Ni-NTA-agarose beads (Qiagen) in the presence of 20 mM imidazole for 1 h at 4° C. Pack beads into a column and wash several times with wash buffer with alternating pHs of 7.4 and 6.0. 20 mM NaH2PO4, 0.5 M NaCl, 20 mM imidazoles, 5 mM β-ME, 10% glycerol. Elute proteins with wash buffer at pH 7.4 containing 300 mM imidazole. Purify complex over Superdex 200 (26/60) column. Elution Buffer: 50 mM Tris pH 7.4, 0.5 M NaCl, 1 mM EDTA, 10% glycerol, 10 mM β-ME. Dialyze peak fractions against
previous Superdex 200 elution buffer containing 20 mM NaCl. Purify over Mono Q (5/50 GL) anion-exchange column. Elute in same buffer as above with linear NaCl gradient (20-600 mM NaCl). Flash-freeze fractions containing protein and store at −80° C. - Cernunnos purification was as follows: It was expressed in E. Coli. Purified over Ni-NTA beads. Fractions were run over a Superdex-200 gel filtration column. Peak fractions were then run over a HiTrap Heparin column and the purified proteins were stored at −80oC.
-
Mix 5 mM Ku, 5 mM DNA-PKcs, 0.5 mM XRCC4/Ligase IV, and 2.5 mM Cernunnos/XLF in End-Joining Buffer. Add protein mix to 10 ng/ul total DNA (800 bp fragments). Incubate at room temperature for 10 min. Add Mg-ATP to final concentrations of 5 mM MgCl2 and 0.1 mM ATP. Total volume is 201 μl. Incubate at 37° C. for 30-45 min. Quench reaction with 2 ul 0.5 M EDTA. QIAQUICK purify DNA. PCR-amplify junction to measure joining efficiency. 1× End-Joining Buffer: 25 mM Tris pH 7.5, 75 mM NaCl, 72.5 mM KCl, 2 mM DTT, 50 μg/ml BSA, 0.025% Triton X-100, 5% Glycerol, 0.1 mM EDTA, 5% PEG MW>8000 kDa. - The nonhomologous end-joining (NHEJ) pathway is conserved in eukaryotes from yeast to humans. Without requiring homologous DNA, NHEJ repairs DNA double-strand breaks produced by xenobiotic agents such as topoisomerase II inhibitors and ionizing radiation, or the cellular pathway for V(D)J recombination of the immunoglobulin genes. Even when the structure of the DNA ends prevents ligation, NHEJ processes the ends and repairs the breaks with high efficiency and minimal nucleotide loss. For ligatable ends such as the blunt signal ends created by V(D)J recombination, NHEJ suppresses processing and repairs the breaks directly. Thus, NHEJ optimizes the preservation of DNA sequence, but the mechanism is not understood.
- Core proteins for NHEJ include Ku, DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and XRCC4/Ligase IV (XL). Ku consists of two subunits, Ku70 and Ku86, binds with high affinity to DNA ends and recruits DNA-PKcs to the ends. DNA-PKcs brings the ends together into a synaptic complex and then undergoes activation of its kinase domain to facilitate later steps in the joining reaction. XL performs the final ligation step.
- When the DNA ends cannot be ligated directly, NHEJ utilizes nuclease and polymerase activities to process the ends. The exo/endonuclease Artemis interacts with DNA-PKcs. Activation of the DNA-PKcs kinase facilitates Artemis endonuclease activity, which opens the hairpin ends created during V(D)J recombination. DNA polymerases mu and lambda interact with Ku and XL in vitro, and add nucleotides to the immunoglobulin light chain and heavy chain junctions, respectively, during V(D)J recombination.
- Two groups recently identified a new NHEJ protein, designated Cernunnos or XRCC4-like factor (XLF); Buck et at. (2006) Cell 124, 287-99; Ahnesorg et al. (2006) Cell 124, 301-13. For simplicity, we will refer to the protein as Cernunnos for the remainder of this paper. Cernunnos was weakly homologous to XRCC4, but the amino acid sequence failed to suggest a potential function. Using purified proteins, we discovered that Cernunnos acting in concert with Ku stimulated XL to ligate one of the two strands from mismatched DNA ends. Furthermore, Cernunnos biased the choice of the ligated strand to optimize preservation of DNA sequence.
- Cernunnos promotes joining of mismatched and non-cohesive ends. We purified Ku, DNA-PKcs, XL, and Cernunnos to apparent homogeneity (
FIG. 1A ), and tested their ability to join cohesive 5′ ends (EcoRI-EcoRI) or cohesive 3′ ends (KpnI-KpnI). To measure joining efficiency, we used quantitative PCR, which amplified junctions produced from one pair of ends. The PCR primers eliminated signals from competing junctions, such as those produced from intramolecular ligation into circular monomers or intermolecular ligation of other ends. Ku, DNA-PKcs and XL joined EcoRI-EcoRI ends and KpnI-KpnI ends with efficiencies of 1.2% to 2.2% (FIG. 1B ,rows 1 and 2). However, addition of Cernunnos had no effect on joining efficiency. - Next, we tested whether Cernunnos might affect the joining of non-cohesive DNA ends. Addition of Cernunnos to Ku, DNA-PKcs and XL stimulated joining of two blunt ends (EcoRV-EcoRV) by 6-fold (
FIG. 1B , row 3). In the absence of Cernunnos, Ku, DNA-PKcs and XL joined blunt ends paired with either 5′ or 3′ overhangs with low and approximately equal efficiencies (rows 4-7). However, addition of Cernunnos stimulated joining 30 and 55-fold for the blunt-3′ ends, EcoRV-KpnI and EcoRV-SacII, and 8 and 9-fold for the blunt-5′ ends, EcoRV-EcoRI and EcoRV-BamHI. Thus, Cernunnos had a larger effect on blunt-3′ ends than on blunt-5′ ends. - Cernunnos also stimulated joining of ends with mismatched overhangs by 40 to 150-fold (rows 8-11). Ku, DNA-PKcs, XL and Cernunnos joined mismatched 5′ overhangs (Acc651-EcoRI, 0.0039%) with 23-fold lower efficiency than mismatched 3′ overhangs (KpnI-SacI, 0.091%). However, Cernunnos facilitated more efficient joining when the 5′ overhangs contained partially complementary sequences (BamHI-EcoRI, 0.25%).
- In summary, Cernunnos exhibited a preference for 3′ overhangs over 5′ overhangs. This preference also occurred when we omitted DNA-PKcs from the joining reaction (
FIG. 6 ). The effect of Cernunnos was specific, since Cernunnos had no effect on ligation of blunt ends to 3′ overhangs by bacteriophage T4 DNA ligase (FIG. 7 ). - Cernunnos requires Ku to promote mismatched end joining by XL. We were particularly interested in the joining of mismatched 3′ overhangs, because they are produced during V(D)J recombination in vivo, and because Cernunnos stimulated their joining by 40-fold in vitro (
FIG. 1B , row 9). Interestingly, purified XL joined KpnI-SacI ends with low but detectable efficiency, but addition of Cernunnos failed to stimulate joining by XL alone (FIG. 2A ). However, even a sub-stoichiometric concentration of Cernunnos (0.05 nM) stimulated joining by XL (0.5 nM) in the presence of Ku (5 nM) and DNA-PKcs (5 nM). A stoichiometric excess of Cernunnos (15 nM) stimulated joining 200-fold, up to a level of nearly 1%. - To determine which proteins were required for joining mismatched ends, we incubated the DNA with Ku, DNA-PKcs, XL and Cernunnos in different combinations (
FIG. 2B ). As single proteins, only XL produced detectable joining of the KpnI-SacI ends. Addition of Ku and DNA-PKcs to XL increased joining efficiency 12-fold. Starting from the reaction with all four protein preparations, we omitted each protein one at a time. Omission of DNA-PKcs reduced joining only 4-fold, but omission of Ku or Cernunnos reduced joining 150-fold or 40 fold, respectively. Note that omission of Cernunnos reduced joining 200-fold when the concentration of Cernunnos was 15 nM rather than 2.5 nM (FIG. 2A ). Significantly, omission of XL eliminated joining activity completely. Thus, Ku, XL and Cernunnos were required for efficient joining of mismatched ends. These data suggested that Cernunnos and Ku stimulated a latent joining activity for mismatched ends contained in Ligase IV. - Cernunnos promotes preservation of 3′ overhangs. To further characterize the joining of mismatched KpnI-SacI ends, we sequenced the junctions created by Ku, DNA-PKcs and XL, with or without addition of Cernunnos. Surprisingly, the sequence from one 3′ overhang was retained in every junction, while the sequence of the other 3′ overhang was lost (
FIG. 3 , upper panels). In the absence of Cernunnos, 21 of the 22 sequenced junctions retained the 3′ KpnI overhang, while only 1 junction retained the SacI overhang. This preference occurred only in the absence of Cernunnos. In the presence of Cernunnos, the 3′ overhangs were retained with equal probability. - We also characterized the joining of blunt ends to 3′ overhangs of four nucleotides (EcoRV-KpnI) or two nucleotides (EcoRV-SacII). In the absence of Cernunnos, most junctions (20 of 29) lost the 3′ overhang, and only a minority (9 of 29) retained the 3′ overhang (
FIG. 3 , middle and lower left panels). In the presence of Cernunnos, 62 of 62 sequenced junctions retained the 3′ overhang (FIG. 3 , right middle and right lower panels). Cernunnos exhibited the same effect when added to Ku and XL in the absence of DNA-PKcs (FIG. 8 ). Thus, the addition of Cernunnos promoted retention of sequences from the 3′ overhangs. - Finally, we characterized the joining of blunt ends to 5′ overhangs (
FIG. 9 ). Cernunnos exhibited only a moderate effect in promoting retention of the 5′ overhang for EcoRV-BamHI ends, and no effect on retention of the 5′ overhang for EcoRV-EcoRI ends. - Ku, XL and Cernunnos ligate one of the two strands from mismatched DNA ends. In an effort to account for the retention or deletion of 3′ overhangs, we examined our purified protein preparations for polymerase or nuclease activities. Polymerase activity was absent, since the joining reactions did not include dNTPs, and joining efficiency was unaffected by addition of dNTPs. Nuclease activity was also absent, since Cernunnos strongly stimulated joining of blunt-3′ ends with retention of 3′ overhanging sequences (
FIG. 3 andFIG. 8 ). Furthermore, Cernunnos, Ku, XL and DNA-PKcs failed to degrade radiolabeled single-strand DNA substrates (FIG. 10 ), and did not delete any nucleotides in 112 junctions from pairs of blunt ends (EcoRV-EcoRV) and cohesive ends (EcoRI-EcoRI and KpnI-KpnI) (FIG. 11 ). - Taken together, our data demonstrated that Cernunnos and Ku stimulated XL to ligate one of the two strands from mismatched DNA ends. Deletion or retention of 3′ overhangs would depend on which strand was ligated. If Ligase IV catalyzes ligation of only one strand from mismatched ends, the 5′ phosphate group of one DNA substrate should be dispensable for ligation. To test this, we removed 5′ phosphates from the DNA substrates with 3′ overhanging KpnI ends or blunt EcoRV ends, and incubated the DNA with Ku, XL and Cernunnos with or without DNA-PKcs (
FIG. 4 ). When we removed the recessed 5′ phosphate on the KpnI end, joining actually increased because of decreased competition from intramolecular circularization of the KpnI substrate. This demonstrated that the 5′ phosphate on the KpnI end was dispensable for joining. By contrast, when we removed the 5′ phosphate from the blunt EcoRV end, joining decreased to the levels observed when both DNA ends lacked 5′ phosphates. Taken together with the junction sequences (FIG. 3 ), these data indicated that Cernunnos stimulated ligation of one strand from each end, joining theoverhanging 3′ hydroxyl on the KpnI end to the 5′ phosphate on the blunt EcoRV end. - We wanted to obtain direct evidence for this mismatched end (MEnd) ligase activity without PCR amplification. Therefore, we designed a gel-based assay with radiolabeled DNA. To unambiguously identify the joined products and improve joining efficiency, we assayed intramolecular joining of linear DNA molecules. Each DNA molecule contained cohesive EcoRI-EcoRI ends, blunt EcoRV-EcoRV ends, or mismatched blunt-3′ EcoRV-KpnI ends (
FIG. 5 ). - We incubated the DNA with Ku, XL and Cernunnos. To detect the joined products by denaturing gel electrophoresis, we cleaved the DNA products with Xmnl, and labeled the ends with [γ-32P]ATP and T4 polynucleotide kinase (
FIG. 5A ). This procedure labeled the 5′ ends of DNA strands terminating at Xmnl, EcoRI, and EcoRV sites. We measured joining by appearance of a higher molecular weight DNA fragment of the appropriate size. To determine whether joining occurred for a specific strand, we removed the radiolabel on one strand or the other by cleaving the DNA with ApoI or MspA1I. - For the cohesive 5′ overhanging EcoRI-EcoRI ends (
FIG. 5B ), Ku, XL and Cernunnos joined 39% of the input DNA. By contrast, T4 ligase joined 89% of the input DNA. For blunt EcoRV-EcoRV ends (FIG. 5C ), Ku, XL and Cernunnos joined 20% and T4 ligase joined 14% of the input DNA. When we removed the radiolabel from one strand by cleaving the DNA with ApoI or MspA1I, 50% of the signal from the higher molecular weight DNA disappeared (FIG. 5C ). Thus, the assay was able to discriminate the joining of one strand versus the other. The junction formed by joining of the blunt EcoRV ends was susceptible to cleavage by the phosphodiesterase activity of EcoRV, indicating that Cernunnos stimulated a ligation event that created a bona fide phosphodiester bond. - For blunt-3′ EcoRV-KpnI ends, Ku, XL and Cernunnos joined 5% of the input DNA (
FIG. 5D ). This was higher than the result from quantitative PCR of the same DNA products, which detected ligation of 1.6% of the input DNA. When we removed the radiolabel from the strand containing the 3′ overhang by MspA1I cleavage, 100% of the signal from the higher molecular weight DNA disappeared. By contrast, removal of the radiolabel from the other strand by ApoI reduced the size of the higher molecular weight fragment by 57 nucleotides without diminishing the signal. This result provided direct evidence for single-strand ligation of the hydroxyl group of the 3′ overhang to the 5′ phosphate of the blunt end. Remarkably, Ku, XL and Cernunnos ligated blunt-3′ ends with an efficiency of 5%, even in the absence of DNA-PKcs. - We propose that Ku, XL and Cernunnos ligate the 3′ overhanging hydroxyl group to the 5′ phosphate of the opposing end. Thus, ligation creates a continuous single strand, which can serve as a template for DNA polymerase. Previously, we showed that human cell extracts recapitulated NHEJ as observed in vivo (Budman and Chu) (2005) EMBO J. 24, 849-60. Extracts join blunt-3′ ends with high efficiency, utilizing polymerase activity to preserve the sequence from the 3′ overhang. MEnd ligase activity explains this phenomenon.
- We speculate that Cernunnos together with Ku and XRCC4 aligns mismatched ends to promote ligation by Ligase IV. It is shown herein that Cernunnos and Ku stimulated XL to join blunt ends and several types of mismatched ends that are non-complementary or partially complementary (
FIG. 1 ). On the other hand, Cernunnos failed to stimulate joining of ends with cohesive 4 nucleotide overhangs. Thus, Cernunnos may be dispensable for cohesive end joining with 4 nucleotide overhangs, but may provide the necessary alignment for XL to join blunt ends, ends that are less cohesive, or ends with mismatched overhangs. - Ma et al. (2004)
Mol Cell 16, 701-13. reported a single-strand ligase activity for XL alone. However, joining required alignment of the ends by at least 2 complementary base pairs, and occurred in the absence of Ku or Cernunnos. As shown herein, Cernunnos and Ku stimulated XL to ligate mismatched ends by more than 100-fold (FIG. 2B ), even when the ends lacked complementary base pairing. Thus, Ku, XL and Cernunnos possess a novel ligase activity for mismatched ends. - In conclusion, the MEnd ligase activity from Ku, XL and Cernunnos preserves sequences by direct ligation of the 3′ overhang to the 5′ phosphate of the opposing end. MEnd ligase activity for mismatched ends has applications for recombinant DNA technology. For example, sheared genomic DNA and PCR-amplified DNA contain 3′ overhangs generated by the shearing process or by the weak TdT activity of Taq polymerase, respectively. MEnd ligase can ligate such DNA molecules directly into a blunt-ended cloning vector.
- Expression constructs and protein purification. We used PCR to amplify the human Cernunnos open reading frame (ORF) from a human cDNA clone (ATCC, MGC-32656), subcloned it into pET101/D-TOPO (Invitrogen), which added a His tag to the C-terminus of the protein, and expressed recombinant Cernunnos in bacteria. We purified Cernunnos from the bacterial lysate to apparent homogeneity on Ni-NTA beads (Qiagen) followed by Superdex-200 (26/60) and Hi-trap heparin columns (Amersham Pharmacia Biotech).
- We purified XRCC4/Ligase IV as described above. Briefly, we infected Sf9 insect cells with baculoviruses containing XRCC4 and Ligase IV-His, lysed the cells, and purified the proteins on Ni-NTA beads (Qiagen) followed by Superdex-200 (26/60) and Mono Q (5/50 GL) columns (Amersham Pharmacia Biotech).
- We purified Ku from lysate of Sf9 cells co-infected with baculoviruses containing Ku70-His and Ku86 by binding to Ni-NTA beads (Qiagen), and gel filtration on a Superose-12 (
HR 10/30) column (Amersham Pharmacia Biotech). - We purified DNA-PKcs from HeLa cells, which were provided as a cell pellet by National Cell Culture Center. We prepared extracts with minor modifications of the protocol by Dvir et al. (1993) J. Biol. Chem. 268, 10440-10447 and purified DNA-PKcs using methods from Ding et al. (2003)
Mol Cell Biol 23, 5836-48. Peak fractions containing Cernunnos, XRCC4/Ligase IV, Ku, and DNA-PKcs were flash-frozen and stored at −80° C. - Preparation of DNA substrates. We prepared DNA substrates for the PCR-based assay as previously described by Budman and Chu (2006) Methods Enzymol 408, 430-44, and prepared DNA substrates for the gel-based assay by PCR amplification of a 1 kb DNA fragment. Digestion of the PCR product with EcoRI or EcoRV, or double digestion with EcoRV and KpnI, released a DNA fragment with EcoRI-EcoRI, EcoRV-EcoRV, or EcoRV-KpnI ends, which was resolved by agarose gel electrophoresis and purified from the gel.
- End-joining reactions. We performed end-joining reactions, purified the DNA products on a QIAquick column (Qiagen), measured joining efficiencies by quantitative PCR, and sequenced the DNA junctions.
- For the gel-based assay, we performed end-joining reactions by incubating 0.4 pmol of the DNA substrate with no protein, or 2 pmol Ku, 0.4 pmol XL, and 2 pmol Cernunnos, or 1 unit of T4 DNA ligase (USB) in NHEJ buffer in a total volume of 200 μL. After incubation, we purified the DNA products on a QIAquick column (Qiagen), digested the DNA with Xmnl at 37° C. for 1 hr, dephosphorylated the DNA with 1 unit Antarctic phosphatase (NEB) at 37° C. for 15 min, and then labeled the DNA with [γ-32P]ATP and T4 polynucleotide kinase (NEB). We purified the DNA by phenol/chloroform extraction and ethanol-precipitation, digested the DNA further with ApoI, MspA1I, or EcoRV, resolved the products by electrophoresis in a TBE-
urea 5% polyacrylamide gel (BioRad), and quantified joining by Phosphorlmager analysis (Molecular Dynamics). - Expression Constructs and Protein Purification. We used PCR to amplify the human Cernunnos ORF from a human cDNA clone (ATCC, MGC-32656) and subcloned it into pET101/D-TOPO (Invitrogen), which added a His tag to the C terminus of the protein. We verified the construct by DNA sequencing and expressed recombinant Cernunnos protein in the bacterial host Rosetta2(DE3)pLysS (EMD Biosciences).
- To purify Cernunnos, we first induced expression by adding IPTG to 0.5 mM and grew cells for 3 h at 30° C., then extracted proteins in Buffer A (50 mM Na.PO4, pH 8.0/2 M NaCl/10 mM imidazole/10 mM 2-βmercaptoethanol/1.5% Igepal CA-650/1 mM phenylmethylsulfonyl fluoride/2 mM benzamidine/EDTA-free protease inhibitor mixture tablet; Roche) and clarified the lysate by centrifugation at 35,000×g for 1 h. Lysate was loaded onto a Ni-NTA column (Qiagen), and bound proteins were eluted with 250 mM imidazole (100% Buffer A). We then pooled the fractions and subjected them to gel filtration on a Superdex-200 column in 1 M NaCl/20 mM Hepes, pH 8.0/10 mM 2-mercaptoethanol/1 mM EDTA/10% glycerol. We analyzed fractions by SDS/PAGE and Coomassie staining, pooled the fractions containing Cernunnos, loaded the pooled fractions onto a 1-ml Hi-Trap heparin column (Amersham Pharmacia Biotech), and applied a linear salt gradient of 150 to 1000 mM NaCl in Na.PO4.
- We purified XRCC4/Ligase IV by infectingSf9 cells with baculoviruses containing XRCC4 and Ligase IV-His (a gift from William Dynan, Medical College of Georgia, Augusta, Ga.), lysed the cells, and purified the proteins on a Ni-NTA column (Qiagen) followed by Superdex-200 (26/60) and Mono Q (5/50 GL) columns (Amersham Pharmacia Biotech).
- We purified Ku70/86 from Sf9 cells coinfected with baculoviruses containing Ku70-His and Ku86 by lysing the cells in Buffer B (50 mM Na.PO4, pH 8.0/500 mM NaCl/1.5% Igepal CA-650/10% glycerol/10 mM 2-mercaptoethanol/1 mM phenylmethylsulfonyl fluoride/2 mM benzamidine/EDTA-free protease inhibitor mixture tablet; Roche) and clarifying the extract with centrifugation. After binding proteins to Ni-NTA beads (Qiagen), we eluted Ku70/86 in Buffer B containing 300 mM imidazole and further purified the heterodimeric complex with a Superose-12 (
HR 10/30) gel filtration column (Amersham Pharmacia Biotech) in 50 mM Na.PO4, pH 7.4/300 mM NaCl/1 mM EDTA/10% glycerol/10 mM 2-mercaptoethanol. We purified DNA-PKcs from 20 liters of cultured HeLa cells, which were provided as a cell pellet by National Cell Culture Center. - We prepared nuclear extracts with minor modifications of the protocol by Dvir et al. In particular, we lysed cells by homogenization in hypotonic lysis buffer (10 mM KCl/10 mM Tris.HCl, pH 7.9/1 mM DTT/1 mM phenylmethylsulfonyl fluoride/2 mM benzamidine/EDTA-free protease inhibitor mixture tablet; Roche), collected cell nuclei by centrifugation at 3,300′g, and lysed the nuclei in buffer containing 50 mM Tris.HCl, pH 7.9/0.42 M KCl/5 mM MgCl2/20% glycerol/10% sucrose/2 mM DTT/1 mM phenylmethylsulfonyl fluoride/2 mM benzamidine/EDTA-free protease inhibitor mixture tablet. We collected nuclear proteins by centrifugation at 26,500×g followed by precipitation of the supernatant with 0.33 g/ml (NH4)2SO4. The pellet was resuspended in 50 mM Tris.HCl, pH 7.9/0.1 M KCl/12.5 mM MgCl2/1 mM EDTA/20% glycerol/1 mM DTT and dialyzed into the same buffer. We purified DNA-PKcs by loading nuclear extract onto a column of NHS-activated HiTrap resin (Invitrogen) conjugated to a Ku86 C-terminal peptide, and eluting bound protein in 25 mM Hepes-KOH, pH 7.5/0.
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/871,023 US8263332B2 (en) | 2006-10-12 | 2007-10-11 | Mismatched end DNA ligase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85159406P | 2006-10-12 | 2006-10-12 | |
US11/871,023 US8263332B2 (en) | 2006-10-12 | 2007-10-11 | Mismatched end DNA ligase |
Publications (2)
Publication Number | Publication Date |
---|---|
US20080160526A1 true US20080160526A1 (en) | 2008-07-03 |
US8263332B2 US8263332B2 (en) | 2012-09-11 |
Family
ID=39584507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/871,023 Expired - Fee Related US8263332B2 (en) | 2006-10-12 | 2007-10-11 | Mismatched end DNA ligase |
Country Status (1)
Country | Link |
---|---|
US (1) | US8263332B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012099896A2 (en) | 2011-01-17 | 2012-07-26 | Life Technologies Corporation | Workflow for detection of ligands using nucleic acids |
-
2007
- 2007-10-11 US US11/871,023 patent/US8263332B2/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012099896A2 (en) | 2011-01-17 | 2012-07-26 | Life Technologies Corporation | Workflow for detection of ligands using nucleic acids |
EP3216878A1 (en) | 2011-01-17 | 2017-09-13 | Life Technologies Corporation | Workflow for detection of ligands using nucleic acids |
EP3567121A1 (en) | 2011-01-17 | 2019-11-13 | Life Technologies Corporation | Workflow for detection of ligands using nucleic acids |
Also Published As
Publication number | Publication date |
---|---|
US8263332B2 (en) | 2012-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11993791B2 (en) | Modification of 3′ terminal ends of nucleic acids by DNA polymerase theta | |
Heiter et al. | Site-specific DNA-nicking mutants of the heterodimeric restriction endonuclease R. BbvCI | |
Roberts et al. | An archaeal XPF repair endonuclease dependent on a heterotrimeric PCNA | |
US20180320162A1 (en) | Engineered ligase variants | |
KR101751554B1 (en) | Phage φ29 dna polymerase chimera | |
US10837009B1 (en) | DNA ligase variants | |
US11046939B2 (en) | DNA polymerase variant | |
CA3080512A1 (en) | Transglutaminase variants | |
CA2802000C (en) | Dna polymerases with increased 3'-mismatch discrimination | |
BR112021008186A2 (en) | engineered dna polymerase, polynucleotide sequence, expression vector, host cell, composition, high-throughput assay system, and, methods for producing a engineered dna polymerase polypeptide in a host cell and for determining high throughput fidelity of a dna polymerase. | |
KR20210031699A (en) | DNA polymerase mutant suitable for nucleic acid amplification reaction from RNA | |
SG186325A1 (en) | Dna polymerases with increased 3'-mismatch discrimination | |
US8263332B2 (en) | Mismatched end DNA ligase | |
Monakhova et al. | Endonuclease activity of MutL protein of the Rhodobacter sphaeroides mismatch repair system | |
KR102382489B1 (en) | Penicillin G acylase | |
Kaplan et al. | Recombinant production of Thermus aquaticus single-strand binding protein for usage as PCR enhancer | |
US20220389397A1 (en) | Deoxyribonuclease variants and uses thereof | |
Martins et al. | Mutational analysis of vaccinia virus nucleoside triphosphate phosphohydrolase I, a DNA-dependent ATPase of the DExH box family | |
US20240182890A1 (en) | Compositions and methods for site-specific modification | |
Zou et al. | Expression and purification of a functional recombinant aspartate aminotransferase (AST) from Escherichia coli | |
US20230220435A1 (en) | Method and kit for assembly of multiple dna fragments at room temperature | |
EP2870241B1 (en) | A composition showing activation-induced cytidine deaminase (aid) activity, a method of preparation of such composition in a bacterial system and use of the composition in the analyses of dna/rna amination/deamination and/or methylation/demethylation | |
WO2024138200A2 (en) | Engineered rna ligase variants | |
US20050255563A1 (en) | Method for plasmid preparation by conversion of open circular plasmid to supercoiled plasmid | |
US20160230156A1 (en) | Recombinant fusion protein possessing nuclease and phosphatase activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TSAI, CHUN;CHU, GILBERT;KIM, SEONHI;REEL/FRAME:020674/0937;SIGNING DATES FROM 20080108 TO 20080303 Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TSAI, CHUN;CHU, GILBERT;KIM, SEONHI;SIGNING DATES FROM 20080108 TO 20080303;REEL/FRAME:020674/0937 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:STANFORD UNIVERSITY;REEL/FRAME:021879/0695 Effective date: 20071016 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20160911 |